





PCT

特許協力条約に基づいて公開された国際出願

(51) 国際特許分類6 C07D 237/24, 237/22, 237/04, 401/06, 401/12, A61K 31/50 // (C07D 401/06, 213:00, 237:00) (C07D 401/12, 213:00, 237:00)		A1	(11) 国際公開番号 WO99/44995
		(43) 国際公開日	1999年9月10日(10.09.99)
(21) 国際出願番号 PCT/JP99/00925	尾田聡一(ODA, Soichi)[JP/JP] 〒189-0022 東京都東村山市野口町2-17-43 Tokyo, (JP)		
(22) 国際出願日 1999年2月26日(26.02.99)	幅田由利子(HABATA, Yuriko)[JP/JP] 〒207-0022 東京都東大和市桜ヶ丘1-1425-3-424 Tokyo, (JP)		
(30) 優先権データ 特願平10/49396 1998年3月2日(02.03.98)	JP	小滝京子(KOTAKI, Kyoko)[JP/JP] 〒350-0205 埼玉県坂戸市東坂戸1-10-404 Saitama, (JP)	
(71) 出願人 (米国を除くすべての指定国について) 興和株式会社(KOWA CO., LTD.)(JP/JP) 〒460-0003 愛知県名古屋市中区錦三丁目6番29号 Aichi, (JP)	(74) 代理人 弁理士 有賀三幸, 外(ARUGA, Mitsuyuki et al.) 〒103-0013 東京都中央区日本橋人形町1丁目3番6号 共同ビル Tokyo, (JP)		
(72) 発明者; および (75) 発明者/出願人 (米国についてのみ) 大口正夫(OHKUCHI, Masao)[JP/JP] 〒359-0041 埼玉県所沢市中新井3-9-5 Saitama, (JP) 京谷善徳(KYOTANI, Yoshinori)[JP/JP] 〒207-0021 東京都東大和市立野3-1293-10 2-112 Tokyo, (JP) 執行洋陸(SHIGYO, Hiromichi)[JP/JP] 〒183-0035 東京都府中市四谷6-18-18 Tokyo, (JP) 古崎栄男(YOSHIZAKI, Hideo)[JP/JP] 〒350-1315 埼玉県狭山市北入曽459-16 Saitama, (JP) 古志朋之(KOSHI, Tomoyuki)[JP/JP] 〒353-0006 埼玉県志木市館2-4-4-206 Saitama, (JP) 北村崇博(KITAMURA, Takahiro)[JP/JP] 松田隆行(MATSUDA, Takayuki)[JP/JP]	(81) 指定国 AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, 欧州特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), ARIPO特許 (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)		
添付公開書類 国際調査報告書			
(54)Title: NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT			
(54)発明の名称 新規ピリダジン誘導体及びこれを有効成分とする医薬			
 <p>(1)</p>			
(57) Abstract Pyridazine derivatives represented by general formula (1) or salts thereof, wherein R ¹ represents lower alkoxy, lower alkylthio or halogeno; R ² represents H, lower alkoxy, lower alkylthio or halogeno; R ³ represents OH, CN, halogeno, lower cycloalkyl, lower alkyl or lower alkenyl optionally substituted by an optionally substituted aromatic group or optionally substituted carbamoyl; R ⁴ represents COOH, lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted amino or optionally substituted ureido; and the broken line means a single bond or a double bond between the carbon atoms at the 4- and 5-positions. Because of having an excellent effect of regulating interleukin-1β production, these compounds are useful as preventives/remedies for immunologic diseases, inflammatory diseases, ischemic diseases, etc.			

(57)要約

本発明は、式(1)



(R¹ は低級アルコキシ基、低級アルキルチオ基又はハロゲン原子を；R² はH、低級アルコキシ基、低級アルキルチオ基又はハロゲン原子を；R³ はOH、CN、ハロゲン原子、低級シクロアルキル基、(置換)芳香族基又は(置換)カルバモイル基で置換されていてもよい低級アルキル基又は低級アルケニル基、R⁴ はCOOH、低級アルコキシカルボニル基、(置換)カルバモイル基、(置換)アミノ基又は(置換)ウレイド基を；破線は4位と5位の炭素間結合が、単結合又は二重結合であることを示す)

で表わされるピリダジン誘導体又はその塩、及びこれを有効成分とする医薬に関する。この化合物は、優れたインターロイキン-1β産生抑制作用を有し、免疫系疾患、炎症性疾患、虚血性疾患等の予防・治療剤として有用である。

PCTに基づいて公開される国際出願のパンフレット第一頁に掲載されたPCT加盟国を同定するために使用されるコード(参考情報)

AE	アラブ首長国連邦	DM	ドミニカ	KZ	カザフスタン	SD	スーダン
AL	アルバニア	EE	エストニア	LC	セントルシア	SE	スウェーデン
AM	アルメニア	ES	スペイン	LI	リヒテンシュタイン	SG	シンガポール
AT	オーストリア	FI	フィンランド	LK	スリ・ランカ	SI	スロヴェニア
AU	オーストラリア	FR	フランス	LR	リベリア	SK	スロヴァキア
AZ	アゼルバイジャン	GA	ガボン	LS	レソト	SL	シエラ・レオネ
BA	ボスニア・ヘルツェゴビナ	GB	英国	LT	リトアニア	SN	セネガル
BB	バルバドス	GD	グレナダ	LU	ルクセンブルグ	SZ	スワジランド
BE	ベルギー	GE	グルジア	LV	ラトヴィア	TD	チャード
BF	ブルキナ・ファソ	GH	ガーナ	MC	モナコ	TG	トーゴ
BG	ブルガリア	GM	ガンビア	MD	モルドヴァ	TJ	タジキスタン
BJ	ベナン	GN	ギニア	MG	マダガスカル	TZ	タンザニア
BR	ブラジル	GW	ギニア・ビサウ	MK	マケドニア旧ユーゴスラヴィア共和国	TM	トルクメニスタン
BY	ベラルーシ	GR	ギリシャ	ML	マリ	TR	トルコ
CA	カナダ	HR	クロアチア	MN	モンゴル	TT	トリニダード・トバゴ
CF	中央アフリカ	HU	ハンガリー	MR	モーリタニア	UA	ウクライナ
CG	コンゴ	ID	インドネシア	MW	マラウイ	UG	ウガンダ
CH	スイス	IE	アイルランド	MX	メキシコ	US	米国
CI	コートジボワール	IL	イスラエル	NE	ニジェール	UZ	ウズベキスタン
CM	カメルーン	IN	インド	NL	オランダ	VN	ヴェトナム
CN	中国	IS	アイスランド	NO	ノルウェー	YU	ユーゴスラビア
CR	コスタ・リカ	IT	イタリア	NZ	ニュージーランド	ZA	南アフリカ共和国
CU	キューバ	JP	日本	PL	ポーランド	ZW	ジンバブエ
CY	キプロス	KE	ケニア	PT	ポルトガル		
CZ	チェコ	KG	キルギスタン				

NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

Patent Number: EP1061077

Publication date: 2000-12-20

Inventor(s): OHKUCHI MASAO (JP); KYOTANI YOSHINORI (JP); SHIGYO HIROMICHI (JP); YOSHIZAKI HIDEO (JP); KOSHI TOMOYUKI (JP); KITAMURA TAKAHIRO (JP); MATSUDA TAKAYUKI (JP); ODA SOICHI (JP); HABATA YURIKO (JP); KOTAKI KYOKO (JP)

Applicant(s): KOWA CO (JP)

Requested Patent: EP1061077

Application Number: EP19990906509 19990226

Priority Number(s): WO1999JP00925 19990226; JP19980049396 19980302

IPC Classification: C07D237/24; C07D237/22; C07D237/04; C07D401/06; C07D401/12; A61K31/50; C07D401/06; C07D213/00; C07D401/12; C07D213/00; C07D237/00

EC Classification: C07D237/02; C07D237/04; C07D237/22; C07D237/24; C07D401/06+237B+213; C07D401/12+237B+213

Equivalents: AU2641499, AU739431, CA2321254, CN1142149C, CN1291979, HK1035194, HU0101461, NO20004353, NZ506144, RU2221790, US6403586, WO9944995

Cited Documents:

Abstract

This invention relates to pyridazine derivatives represented by the formula (1): wherein R<1> represents a lower alkoxy group, a lower alkylthio group or a halogen atom; R<2> represents H, a lower alkoxy group, a lower alkylthio group or a halogen atom; R<3> represents a lower alkyl or lower alkenyl group, which may be substituted by one or more OHs, CNs, lower cycloalkyl groups, (substituted) aromatic groups or (substituted) carbamoyl groups; R<4> represents COOH, a lower alkoxycarbonyl group, a (substituted) carbamoyl group, a (substituted) amino group, or a (substituted) ureido group; and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin-1 beta production, and are useful as preventives and therapeutics for immune system diseases, inflammatory diseases, ischemic diseases and the like.

Data supplied from the esp@cenet database - I2

Description

Technical Field

[0001] This invention relates to novel pyridazine derivatives, which have excellent inhibitory activity against interleukin-1 beta production and are useful for the prevention and treatment of immune system diseases, inflammatory diseases, ischemic diseases and the like, and also to medicines containing them as effective ingredients.

Background Art

[0002] In many diseases, for example, rheumatism, arthritis, osteoporosis, inflammatory colitis, immune deficiency syndrome, ichorrhemia, hepatitis, nephritis, ischemic diseases, insulin-dependent diabetes mellitus, arterial sclerosis, Parkinson's disease, Alzheimer's disease, leukemia and the like, stimulation of interleukin-1 beta production, an inflammatory cytokine, is observed. This interleukin-1 beta serves to induce synthesis of an enzyme which is considered to take part in inflammation like collagenase and PLA2 and, when intra-articularly injected to animals, causes multi-articular destruction highly resembling rheumatoid arthritis. On the other hand, interleukin-1 beta is controlled in activity by interleukin-1 receptor, soluble interleukin-1 receptor and interleukin-1 receptor antagonist.

[0003] From research conducted making use of recombinants of these bioactivity-inhibiting substances, anti-interleukin-1 beta antibodies and anti-receptor antibodies against various disease models, interleukin-1 beta has been found to play an important role in the body, leading to an increasing potential of substances having interleukin-1 beta inhibitory activity as therapeutics for such diseases.

[0004] For example, immunosuppressors and steroids which are used for the treatment of rheumatism out of such many diseases have been reported to inhibit the production of interleukin-1 beta. Even among medicaments currently under development, KE298, a benzoylpropionic acid derivative [The Japanese Society of Inflammation (11th), 1990], for example, has been reported to have inhibitory activity against interleukin-1 beta production although it is an immunoregulator. Inhibitory activity against interleukin-1 beta production is also observed on a group of compounds which are called "COX-2 selective inhibitors", for example, nimesulide as a phenoxysulfonanilide derivative (DE 2333643), T-614 as a phenoxybenzopyran derivative (US 4954518), and tenidap (hydroxyindole derivative) as a dual inhibitor (COX-1/5-LO).

[0005] For all of these compounds, however, interleukin-1 beta production inhibitory activity is not their primary action so that their inhibitory activity against interleukin-1 beta production is lower than their primary action.

[0006] In recent years, increasingly active research is under way for the synthesis of compounds with a focus placed on inhibitory activity against interleukin-1 beta production. Inhibitors synthesized in such research can be classified into a group of compounds which inhibit the transfer process of an inflammatory signal to a cell nucleus and another group of compounds which inhibit an enzyme ICE that functions in the processing of a precursor of interleukin-1 beta. Known examples of compounds presumed to have the former action include SB203580 [Japanese Language Laid-Open (Kokai) Publication (PCT) No. HEI 7-503017], FR167653 (Eur. J. Pharm., 327, 169-175, 1997), E-5090 (EP 376288), CGP47969A (Gastroenterology, 109, 812-828, 1995), hydroxyindole derivatives (Eur. J. Med. Chem. 31, 187-198, 1996), and triarylpyrrole derivatives (WO 97/05878), while known examples of compounds presumed to have the latter action include VE-13,045 which is a peptide compound (Cytokine, 8(5), 377-386, 1996).

[0007] None of these compounds can however exhibit sufficient inhibitory activity against interleukin-1 beta production.

[0008] On the other hand, it is known that a variety of 5,6-diphenylpyridazine derivatives have analgesic and anti-inflammatory action (EUR. J. MED. CHEM., 14, 53-60, 1979) and also that 3,4,5,6-substituted pyridazine derivatives have inhibitory activity against interleukin-1 beta converting enzymes [Japanese Patent Application Laid-Open (Kokai) No. HEI 7-69894]. Absolutely nothing has however been known with respect to inhibitory activity of 2,4,6-substituted pyridazin-3-one derivatives against interleukin-1 beta production.

[0009] Accordingly, an object of the present invention is to provide a compound having excellent inhibitory activity against interleukin-1 beta production and also a medicine containing it as an effective ingredient.

Disclosure of the Invention

[0010] Under such circumstances, the present inventors have proceeded with an extensive investigation. As a result, it has been found that pyridazine derivatives represented by the below-described formula (1) have excellent inhibitory activity against interleukin-1 beta production and are

useful for the prevention and treatment of immune system diseases, inflammatory diseases, ischemic diseases and the like, leading to the completion of the present invention.

[0011] Namely, the present invention provides a pyridazine derivative represented by the following formula (1):

wherein R represents a lower alkoxy group, a lower alkylthio group or a halogen atom; R represents a hydrogen atom, a lower alkoxy group, a lower alkylthio group or a halogen atom; R represents a linear or branched lower alkyl or lower alkenyl group, which may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group, a lower cycloalkyl group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted carbamoyl group; R represents a carboxyl group, a lower alkoxycarbonyl group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted thiocarbamoyl group, a substituted or unsubstituted amino group, or a substituted or unsubstituted ureido group; and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond; or a salt thereof.

[0012] Further, the present invention also provides a medicine comprising the pyridazine derivative (1) or the salt thereof as an effective ingredient.

[0013] Furthermore, the present invention also provides a pharmaceutical composition comprising the pyridazine derivative (1) or the salt thereof and a pharmaceutically acceptable carrier.

[0014] Moreover, the present invention also provides use of the pyridazine derivative (1) or the salt thereof as a medicine.

[0015] In addition, the present invention also provides a method for treating a disease caused by stimulation of interleukin-1 beta production, which comprises administering the pyridazine derivative (1) or the salt thereof.

Best Mode for Carrying out the Invention

[0016] The pyridazine derivative according to the present Invention is represented by the formula (1). In the formula, illustrative of the lower alkoxy groups represented by R and R can be those having 1 to 6 carbon atoms, for example, methoxy, ethoxy and propoxy. Illustrative of the lower alkylthio groups can be those having 1 to 6 carbon atoms, for example, methylthio, ethylthio and propylthio. Illustrative of the halogen atoms can be fluorine, chlorine, bromine and iodine.

[0017] Preferred as R is a fluorine atom, a lower alkoxy group or a lower alkylthio group, while preferred as R is a hydrogen atom, a halogen atom or a lower alkoxy group.

[0018] Examples of the lower alkyl group out of those represented by R can include linear or branched lower alkyl groups having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl and n-butyl. Examples of the lower alkenyl group can include linear or branched lower alkenyl groups having 2 to 9 carbon atoms, more preferably 2 to 6 carbon atoms and 1 to 3 double bonds, for example, ethenyl, propenyl and butenyl.

[0019] These lower alkyl groups and lower alkenyl groups may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group, a lower cycloalkyl group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted carbamoyl group.

[0020] Examples of the lower cycloalkyl group can include those having 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0021] Examples of the aromatic group can include aromatic hydrocarbon groups and aromatic heterocyclic groups, for example, phenyl, naphthyl and pyridyl, with phenyl and pyridyl being particularly preferred. These aromatic groups may each contain 1 to 3 substituents. Examples of such substituents can include halogens, nitro, amino, and aromatic-group-substituted carbonylamino groups. Illustrative of aromatic group(s) substituted on the carbonylamino group can be phenyl and pyridyl.

[0022] Illustrative of substituent(s) which the carbamoyl group may have can be lower alkyl groups, lower alkyl groups each of which may be substituted by one or more hydroxyl groups or aromatic groups, and aromatic groups each of which may be substituted by one or more lower alkylthio groups.

[0023] Further, examples of the halogen atoms, aromatic groups, lower alkyl groups and lower alkylthio groups can be similar ones as those exemplified above (including those exemplified as R and R).

[0024] R may preferably be an alkyl group having 1 to 6 carbon atoms or a lower alkenyl group having 2 to 9 carbon atoms, which may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group or a lower cycloalkyl group; a phenyl or pyridyl group which may have 1 to 3 substituents each independently selected from a halogen atom, a nitro group, an amino group or an aromatic-group-substituted carbonylamino group; or a carbamoyl group which may have one or more substituents each independently selected from a lower alkyl groups, hydroxy lower alkyl group, an aromatic-group-substituted lower alkyl group or a lower alkylthiophenyl group.

[0025] Examples of the lower alkoxy carbonyl group out of those represented by R can include carbonyl groups each of which has an alkoxy group having 1 to 6 carbon atoms, for example, methoxycarbonyl, ethoxycarbonyl and butoxycarbonyl.

[0026] Examples of the substituent(s) in the substituted carbamoyl or thiocarbamoyl group can include lower alkyl groups, which may have one or more substituents such as aromatic groups, and aromatic groups.

[0027] Examples of the substituent(s) in the substituted amino group can include lower alkoxy carbonyl groups each of which may have one or more substituents such as aromatic groups; acyl groups; lower alkyl groups each of which may have one or more substituents such as aromatic groups; and lower alkylsulfonyl groups. Illustrative of the acyl groups can be those having 1-5 carbon atoms, for example, formyl, acetyl, propionyl and butyryl.

[0028] Examples of the substituent(s) in the substituted ureido group can include lower alkyl groups.

[0029] Incidentally, specific examples of the individual groups, such as the lower alkyl group, aromatic group and lower alkoxy group, represented by R can be similar to those exemplified above with respect to R, R and R.

[0030] R may preferably be a carboxyl group; a lower alkoxy carbonyl group; a carbamoyl or thiocarbamoyl group which may have one or more substituents each independently selected from a lower alkyl group, an aromatic group or an aromatic-group-substituted lower alkyl group; an amino group which may have one or more substituents each independently selected from a lower alkoxy carbonyl group, an aromatic-group-substituted lower alkoxy carbonyl group, an acyl group; a lower alkyl group, an aromatic-group-substituted lower alkyl group or a lower alkylsulfonyl group; or a ureido group which may have one or more lower alkyl groups as substituents.

[0031] Further, the dashed line in the formula (1), namely, the carbon-carbon bond between the 4-position and the 5-position may preferably be a double bond.

[0032] Preferred examples of the pyridazine derivative (1) can include those represented by the same formula in which R represents a fluorine atom, a lower alkoxy group or a lower alkylthio group; R represents a hydrogen atom, a halogen atom or a lower alkoxy group; R represents a linear or branched lower alkyl group having 1 to 6 carbon atoms or a linear or branched lower alkenyl group having 2 to 9 carbon atoms, which may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group, a lower cycloalkyl group; a phenyl or pyridyl group which may have 1 to 3 substituents each independently selected from a halogen atom, a nitro group, an amino group or an aromatic-group-substituted carbonyl-amino group; or a carbamoyl group which may have one or more substituents each independently selected from a lower alkyl group, a hydroxy lower alkyl group, an aromatic-group-substituted lower alkyl group or a lower alkylthiophenyl group; and R represents a carboxyl group; a lower alkoxy carbonyl group; a carbamoyl or thiocarbamoyl group which may have one or more substituents each independently selected from a lower alkyl group, an aromatic group or an aromatic-group-substituted lower alkyl group; an amino group which may have one or more substituents each independently selected from a lower alkoxy carbonyl group, an aromatic-group-substituted lower alkoxy carbonyl group, an acyl group, a lower alkyl groups, an aromatic-group-substituted lower alkyl group or a lower alkylsulfonyl group; or a ureido group which may have one or more lower alkyl groups as substituents.

[0033] Specific preferred examples can include 2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-(cyclopropylmethyl)-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-(cyclopropylmethyl)-4-ethylcarbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one, 2-(4-chlorocinnamyl)-

4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one, or 2-(4-chlorocinnamyl)-4-formylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one.

[0034] No particular limitation is imposed on the salt of the pyridazine (1), said salt also pertaining to the present invention, insofar as it is a pharmacologically acceptable salt. Illustrative can be acid addition salts of mineral acids, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate and phosphate; and acid addition salts of organic acids, such as the benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, oxalate, maleate, fumarate, tartrate and citrate.

[0035] Further, the compounds according to the present invention may exist in the form of solvates represented by hydrates and also in the form of keto-enol tautomers. Such solvates and isomers should also be encompassed by the present invention.

[0036] The pyridazine derivatives (1) according to the present invention can be prepared, for example, by the following processes.

wherein R represents a lower alkyl group, R and R each independently represent a hydrogen atom, a substituted or unsubstituted lower alkyl group or an aromatic group, R represents a substituted or unsubstituted lower alkyl group, R represents a substituted or unsubstituted lower alkyl group, R represents an acyl group, a lower alkylsulfonyl, or a substituted or unsubstituted carbamoyl group, X represents an oxygen atom or a sulfur atom, and R, R and R have the same meanings as defined above.

[0037] A description will be made specifically about respective preparation processes of compounds (1a), (1b), (1c), (1d), (1e), (1f), (1g), (1h) and (1i) among the pyridazine derivatives (1).

(1) Preparation of compounds (1a) of the formula (1) in which R is a lower alkoxy carbonyl group and a double bond is formed between the 4-position and the 5-position:

Each compound (1a) can be obtained by reacting a compound (3), which has been obtained by esterifying a compound (2) by a method known per se in the art, with a compound (5), which is represented by R-Y wherein R has the same meaning as defined above and Y represents a halogen atom or an OH group already converted into a reactive ester group, in the presence of a base in a solvent.

The compound (2) employed here can be prepared, for example, by the process disclosed in Japanese Patent Application Laid-Open (Kokai) No. HEI 7-69894.

As the reactive ester group of the hydroxyl group, a tosyloxy group, a mesyloxy group, a benzenesulfonyloxy group or the like is preferred. A compound which contains such a group can be obtained by reacting para-toluenesulfonyl chloride, methanesulfonyl chloride, methanesulfonic anhydride, benzenesulfonyl chloride or the like with a hydroxyl derivative in the presence of a base such as pyridine, triethylamine or collidine. The reaction is brought to completion at -15 to 50 DEG C in 1 to 50 hours, preferably at -5 to 30 DEG C in 1 to 10 hours. As a solvent, pyridine, tetrahydrofuran, diethyl ether, ethyl acetate, methylene chloride, chloroform, N,N-dimethylformamide, dimethyl sulfoxide or the like can be used.

Examples of the base for use in the reaction between the compound (3) and the compound (5) can include inorganic bases such as potassium carbonate and sodium carbonate and organic bases such as pyridine, triethylamine, and 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU). Usable examples of the solvent can include N,N-dimethylformamide, dimethylsulfoxide, acetone, methyl ethyl ketone, chloroform, methylene chloride, toluene, and benzene. The reaction is brought to completion at 20 to 150 DEG C in 1 to 20 hours, preferably at 50 to 130 DEG C in 2 to 10 hours.

Among the compounds (1a), one containing an aminophenylalkyl group as R can be obtained by reducing the nitro group of a compound (1a) in which R is a nitrophenylalkyl group. Further, N-acylation of the aminophenylalkyl group makes it possible to obtain a compound in which R is an N-acylaminophenylalkyl group.

(2) Preparation of compounds (1b) of the formula (1) in which R is a substituted or unsubstituted carbamoyl group and a double bond is formed between the 4-position and the 5-position:

Each compound (1b) can be obtained by reacting in a solvent the compound (3) with an amine, which is represented by RRNH₂ in which R and R have the same meanings as defined above, to give the compound (4), followed by reacting it as a raw material in a similar manner as in the reaction between

the compound (3) and the compound (5). In the reaction between the compound (3) and the amine, it is preferable to use the amine in an amount of from 1 to 30 equivalents, especially from 2 to 15 equivalents relative to the compound (3). Usable examples of the solvent can include methanol, ethanol, isopropanol, tetrahydrofuran, and N,N-dimethylformamide. The reaction is brought to completion at -10 to 200 DEG C in 0.5 to 24 hours, preferably at 20 to 150 DEG C in 0.5 to 3 hours.

On the other hand, the reaction between the compound (4) and the compound (5) is brought to completion at 20 to 150 DEG C in 1 to 20 hours, preferably at 50 to 130 DEG C in 2 to 10 hours.

Among the compounds (1b), one containing an arylalkylcarbamoylalkyl group or a hydroxyalkylcarbamoylalkyl group as R can be obtained by reacting an arylalkylamine or a hydroxyalkylamine with a compound (1b) in which R is an alkoxycarbonylalkyl group.

Each of the compounds (1b) can also be obtained by reacting the compound (1a) as a raw material in a similar manner as in the reaction conducted upon conversion of the compound (3) into the compound (4).

(3) Preparation of compounds (1i) of the formula (1) in which R is a substituted or unsubstituted carbamoyl group and a single bond is formed between the 4-position and the 5-position:

Each compound (1i) can be obtained by subjecting the compound (1b) to catalytic reduction in a manner known per se in the art. The reaction can be conducted by effecting hydrogenation at room temperature or under heating in the presence of palladium on charcoal, Raney nickel or the like as a catalyst in a solvent such as methanol, ethanol or ethyl acetate.

(4) Preparation of compounds (1c) of the formula (1) in which R is a carboxyl group and a double bond is formed between the 4-position and the 5-position:

Each compound (1c) can be obtained by hydrolyzing the compound (1a) under acidic or basic conditions in a solvent by a method known per se in the art.

Examples of an acid can include hydrochloric acid, sulfuric acid and trifluoroacetic acid, while examples of a base can include sodium hydroxide, potassium hydroxide and barium hydroxide. Usable examples of the solvent can include mixed solvents of water with methanol, ethanol, isopropanol, tetrahydrofuran, N,N-dimethylformamide and the like. The reaction is brought to completion at 0 to 150 DEG C in 10 minutes to 5 hours, preferably at 20 to 100 DEG C in 30 minutes to 2 hours.

(5) Preparation of compounds (1d) of the formula (1) in which R is a substituted or unsubstituted alkoxycarbonylamino group and a double bond is formed between the 4-position and the 5-position:

Each compound (1d) can be obtained by reacting a compound (1c) with an alcohol, which is represented by ROH in which R has the same meaning as defined above, and diphenylphosphoryl azide (DPPA) in the presence of a base in a solventless manner or in a solvent.

Examples of the solvent can include benzene and toluene. Usable examples of the base can include triethylamine. The reaction is brought to completion at 50 to 150 DEG C in 0.5 to 24 hours, preferably at 80 to 120 DEG C in 1 to 8 hours.

(6) Preparation of compounds (1e) of the formula (1) in which R is an amino group substituted by a substituted or unsubstituted lower alkyl group and a lower alkoxycarbonyl group and a double bond is formed between the 4-position and the 5-position:

Each compound (1e) can be obtained by reacting a compound (1d) with a compound, which is represented by R-Y wherein R and Y have the same meanings as defined above, in the presence of a base in a solvent. The reaction can be conducted in a similar manner as the above-described reaction between the compound (3) and the compound (5).

(7) Preparation of compounds (1f) of the formula (1) in which R is an amino group substituted by a substituted or unsubstituted lower alkyl group and a double bond is formed between the 4-position and the 5-position:

Each compound (1f) can be obtained by hydrolyzing a compound (1e) under acidic or basic conditions in a solvent by a method known per se in the art.

Examples of an acid can include hydrochloric acid and sulfuric acid, while examples of a base can include sodium hydroxide, potassium hydroxide and barium hydroxide. Usable examples of the solvent can include mixed solvents of water with methanol, ethanol, isopropanol, tetrahydrofuran, N,N-dimethylformamide and the like. The reaction is brought to completion at 0 to 180 DEG C in 10 minutes to 24 hours, preferably at 20 to 120 DEG C in 0.5 to 8 hours.

(8) Preparation of compounds (1g) of the formula (1) in which R is an amino group and a double bond

is formed between the 4-position and the 5-position:

Each compound (1g) can be obtained by hydrolyzing the compound (1d) under acidic or basic conditions in a solvent by a method known per se in the art.

Examples of an acid can include hydrochloric acid and sulfuric acid, while examples of a base can include sodium hydroxide, potassium hydroxide and barium hydroxide. Usable examples of the solvent can include mixed solvents of water with methanol, ethanol, isopropanol, tetrahydrofuran, N,N-dimethylformamide and the like. The reaction is brought to completion at 0 to 180 DEG C in 10 minutes to 24 hours, preferably at 2 to 120 DEG C in 0.5 to 8 hours.

(9) Preparation of compounds (1h) of the formula (1) in which R is an acylamino group, a lower alkylsulfonylamino group or a substituted or unsubstituted ureido group and a double bond is formed between the 4-position and the 5-position:

(i) Each compound (1h) in which R is an acylamino group can be obtained by reacting a compound (1g) with a compound, which is represented by RCOX or (RCO)₂O wherein R represents a lower alkyl group, an aryl group or a lower aralkyl group and X represents a halogen atom, in the presence of a base in a solvent.

Examples of the solvent can include pyridine, tetrahydrofuran, dioxane, ethyl acetate, chloroform, toluene and benzene. It is also possible to use a mixed solvent of water and ethyl acetate, chloroform, toluene, benzene or the like. Usable examples of the base can include organic bases such as pyridine, triethylamine and DBU and inorganic bases such as sodium hydroxide, potassium hydroxide, potassium carbonate and sodium carbonate. The reaction is brought to completion at -15 to 100 DEG C in 1 to 50 hours, preferably at -5 to 50 DEG C in 2 to 25 hours.

(ii) Each compound (1h) in which R is a lower alkylsulfonylamino group can be obtained by reacting, in a solvent and in the presence of a base, the compound (1g) with 2 equivalents or more of a compound, which is represented by RSO₂X or (RSO₂)₂O wherein R and X have the same meanings as defined above in a similar manner as in the process (i), to give a di(lower alkyl-sulfonyl)amino derivative, followed by hydrolyzing it under basic conditions in a solvent.

Examples of the solvent for use in the hydrolysis can include mixed solvents of water and methanol, ethanol, isopropanol, tetrahydrofuran, N,N-dimethylformamide and the like. Usable examples of the base can include organic bases such as pyridine and inorganic bases such as sodium hydroxide, potassium hydroxide, potassium carbonate and sodium carbonate. The reaction is brought to completion at -15 to 100 DEG C in 10 minutes to 10 hours, preferably at 0 to 80 DEG C in 0.5 to 5 hours.

(iii) Each compound (1h) in which R is a substituted or unsubstituted ureido group can be obtained by reacting the compound (1g) with a compound, which is represented by RNCO wherein R has the same meaning as defined above, in a solvent.

Usable examples of the solvent can include toluene and benzene. The reaction is brought to completion at 20 to 150 DEG C in 0.5 to 30 hours, preferably at 50 to 120 DEG C in 1 to 8 hours.

(10) Compounds (1b) or compounds (1i) of the formula (1) in each of which R is a substituted or unsubstituted thiocarbamoyl group can each be obtained by converting X of the compound (1b) or the compound (1i), in which X is an oxygen atom, into a sulfur atom. For example, X in the compound (1b) in which X is an oxygen atom can be converted into a sulfur atom by reacting the compound (1b) with Lawesson's reagent [2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide] in a solvent. It is preferred to use Lawesson's reagent in 0.5 to 3 equivalents, notably 1 to 1.5 equivalents relative to the compound (1b). The reaction is brought to completion at 30 to 150 DEG C in 1 to 20 hours, preferably at 50 to 100 DEG C in 5 to 15 hours. Usable examples of the solvent can include toluene and xylene.

(11) Preparation of compounds (1i) of the formula (1) in which R is a substituted or unsubstituted carbamoyl group or thiocarbamoyl group and a single bond is formed between the 4-position and the 5-position:

Each compound (1i) can be prepared by hydrogenating the compound (1b), in which R is a substituted or unsubstituted carbamoyl group or thiocarbamoyl group, in a solvent in the presence of palladium on charcoal or the like as a catalyst. Usable examples of the solvent can include methanol, ethanol, isopropanol, tetrahydrofuran, ethyl acetate, and N,N-dimethylformamide. The reaction is brought to completion at 15 to 200 DEG C in 1 to 50 hours, preferably at 50 to 120 DEG C in 2 to 20 hours.

[0038] The intermediates and target compounds obtained in the above-described individual reactions

can be separated and purified by purification methods commonly employed in organic synthesis chemistry, for example, by subjecting them to filtration, extraction, washing, drying, concentration, recrystallization, various chromatographic treatment, and the like. The intermediates may be provided for the next reactions without purifying them specifically. Further, they may also be obtained as solvates of solvents such as reaction solvents or recrystallization solvents, especially as hydrates.

[0039] The pyridazine derivatives (1) and their salts according to the present invention, which are available as described above, have excellent inhibitory activity against interleukin-1 beta production, and are useful for the prevention and treatment of diseases caused by stimulation of interleukin-1 beta production, for example, immune system diseases, inflammatory diseases, ischemic diseases, osteoporosis, ichorrhemia and the like, especially as medicines such as preventives and therapeutics for rheumatism, immune deficiency syndrome, arthritis, inflammatory colitis, ischemic heart diseases, ischemic encephalopathy, ischemic nephritis, ischemic hepatitis, insulin-dependent diabetes mellitus, arterial sclerosis, Parkinson's disease, Alzheimer's disease, leukemia and the like or as interleukin-1 beta production inhibitors.

[0040] Medicines according to the present invention contain the pyridazine derivatives (1) or their salts as effective ingredients. Their administration routes can include, for example, oral administration by tablets, capsules, granules, powders, syrups or the like and parenteral administration by intravenous injections, intramuscular injections, suppositories, inhalants, transdermal preparations, eye drops, nasal drops or the like. Upon formulation of pharmaceutical compositions of these various unit dosage forms, the effective ingredients can be used singly or in combination with pharmaceutically acceptable carriers, for example, excipients, binders, extenders, disintegrators, surfactants, lubricants, dispersants, buffers, preservatives, corrigents, perfumes, coating agents, vehicles, diluents or the like, as desired.

[0041] The dosage of each medicine according to the present invention varies depending on the age, body weight, conditions, administration form, administration frequency and the like. In general, however, it is preferred to orally or parenterally administer to an adult the effective ingredient in an amount of about 0.01 to 1,000 mg, preferably 0.1 to 100 mg per day at once or in several portions.

Examples

[0042] The present invention will next be described in further detail by the following Examples. It should however be borne in mind that the present invention is not limited to these Examples.

Example 1

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one

[0043] Potassium carbonate (346 mg, 2.50 mmol) and methyl iodide (284 mg, 2.00 mmol) were added to a solution of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (260 mg, 1.00 mmol) in N,N-dimethylformamide (5 ml), followed by stirring at 60 DEG C for 2 hours. Inorganic matter was filtered off, the solvent was distilled off under reduced pressure, and the residue was then separated and purified by chromatography on a silica gel column [silica gel: 20 g, ethyl acetate/hexane (2/1)]. Crystallization was conducted from chloroform-hexane, whereby the title compound (233 mg, 85.0%) was obtained as yellow needles.

Melting point: 109.2-109.5 DEG C

¹H-NMR (CDCl₃) delta : 3.87(3H,s), 3.92(3H,s), 3.97(3H,s), 6.99(2H,d,J=8.9Hz), 7.75(2H,d,J=8.9Hz), 8.23(1H,s).

IR (KBr) cm: 1743,1713,1660,1607,1518,1278,1250,1141, 1120,1101,839.

Mass (m/z): 274 (M).

Example 2

Preparation of 2-ethyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0044] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and ethyl iodide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 79.4%.

Pale yellow needles (chloroform-hexane)

Melting point: 76.5-77.6 DEG C

H-NMR (CDC I 3) delta : 1.46(3H,t,J=7.2Hz), 3.87(3H,s), 3.98(3H,s), 4.35(2H,q,J=7.2Hz), 6.99(2H,d,J=8.9Hz), 7.76(2H,d,J=8.9Hz), 8.22(1H,s).

IR (KBr) cm: 1749,1721,1712,1661,1599,1519,1272.

Mass (m/z): 288 (M).

Example 3

Preparation of 2-cyanomethyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-2-one

[0046] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and bromoacetonitrile as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 77.4%.

Yellow prisms (chloroform-hexane)

Melting point: 128.0-129.8 DEG C (dec.)

H-NMR (CDC I 3) delta : 3.88(3H,s), 4.00(3H,s), 5.15(2H,s), 7.01(2H,d,J=9.0Hz), 7.78(2H,d,J=9.0Hz), 8.31(1H,s).

IR (KBr) cm: 1721,1669,1608,1520,1313,1276,1251.

Mass (m/z): 299 (M).

Example 4

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-n-propyl-2H-pyridazin-3-one

[0048] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and bromopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 78.3%.

Pale yellow needles (chloroform-hexane)

Melting point: 104.8-105.8 DEG C

H-NMR (CDC I 3) delta : 1.00(3H,t,J=7.4Hz), 1.84-1.99(2H,m), 3.87(3H,s), 3.98(3H,s), 4.26

(2H,t,J=7.4Hz), 6.99(2H,d,J=8.9Hz), 7.75(2H,d,J=8.9Hz), 8.21(1H,s).
 IR (KBr) cm: 1718,1668,1609,1519,1316,1277,1253,1187, 1021,838,797.
 Mass (m/z): 302 (M).

Example 5

Preparation of 2-(2-cyanoethyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0050] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 3-chloropropionitrile as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 78.9%.

Yellow prisms (chloroform-hexane)

Melting point: 140.6-143.1 DEG C
 H-NMR (CDC I 3) delta : 2.99(2H,t,J=6.7Hz), 3.87(3H,s), 3.99(3H,s), 4.56(2H,t,J=6.7Hz), 7.00(2H,d,J=9.0Hz), 7.77(2H,d,J=9.0Hz), 8.28(1H,s).
 IR (KBr) cm: 2246,1717,1664,1520,1275,1250.
 Mass (m/z): 313 (M).

Example 6

Preparation of 2-(2-chloroethyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0052] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 1-bromo-2-chloroethane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 88.8%.

Yellow needles (chloroform-hexane)

Melting point: 97.2-97.7 DEG C
 H-NMR (CDC I 3) delta : 1.43(3H,t,J=7.3Hz), 3.87(3H,s), 3.97(2H,t,J=6.4Hz), 4.45(2H,q,J=7.3Hz), 4.61(2H,t,J=6.4Hz), 7.00(2H,d,J=8.9Hz), 7.75(2H,d,J=8.9Hz), 8.21(1H,s).
 IR (KBr) cm: 1707,1673,1605,1523,1389,1321,1275,1261, 1184,1130,1034,842.
 Mass (m/z): 338 (M), 336 (M).

Example 7

Preparation of 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-vinyl-2H-pyridazin-3-one and 4-ethoxycarbonyl-2-(2-hydroxyethyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0054] Potassium carbonate (115 mg, 0.83 mmol) was added to a solution of 2-(2-chloroethyl)-4-

ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (140 mg, 0.15 mmol) in N,N-dimethylformamide (1 mL), followed by stirring at 80 DEG C for 2 hours. Inorganic matter was filtered off, the solvent was distilled off under reduced pressure, and the residue was then subjected to chromatography on a silica gel column (silica gel: 5 g). From ethyl acetate/hexane (1/2) eluate fractions, the title compound [4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-vinyl-2H-pyridazin-3-one; 34 mg, 27.2%) was obtained as a yellow oil.

H-NMR (CDC l 3) delta : 1.42(3H,t,J=7.1Hz), 3.87(3H,s), 4.44(2H,q,J=7.1Hz), 5.10(1H,d,J=8.5Hz), 5.95(1H,d,J=8.5Hz), 7.00(2H,d,J=8.8Hz), 7.80(2H,d,J=8.8Hz), 7.87(1H,dd,J=8.5,15.6Hz), 8.18(1H,s).

[0055] Subsequently, from chloroform/methanol (20/1) eluate fractions, the title compound [4-ethoxycarbonyl-2-(2-hydroxyethyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (93 mg, 70.4%) was obtained as yellow crystals.

Yellow needles (chloroform-hexane)

Melting point: 104.6-105.4 DEG C

H-NMR (CDC l 3) delta : 1.41(3H,t,J=7.3Hz), 2.75(1H,br), 3.86(3H,s), 4.11(2H,t,J=5.1Hz), 4.44(2H,q,J=7.3Hz), 4.50(2H,t,J=5.1Hz), 6.99(2H,d,J=8.6Hz), 7.73(2H,d,J=8.6Hz), 8.19(1H,s).

IR (KBr) cm: 3426,1717,1706,1655,1596,1520,1389,1316, 1266,1027,831,795.

Mass (m/z): 318 (M).

Example 8

Preparation of 6-(3-chloro-4-fluorophenyl)-2-cinnamyl-4-ethoxycarbonyl-2H-pyridazin-3-one

[0057] Using 6-(3-chloro-4-fluorophenyl)-4-ethoxy-carbonyl-2H-pyridazin-3-one and cinnamyl bromide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 59.3%.

Pale yellow oil

H-NMR (CDC l 3) delta : 1.43(3H,t,J=7.3Hz), 4.45(2H,q,J=7.3Hz), 5.04(2H,dd,J=1.0,6.6Hz), 6.44(1H,td,J=6.6,15.8Hz), 6.77(1H,d,J=15.8Hz), 7.21-7.41(7H,m), 7.90(1H,dd,J=2.3,6.9Hz), 8.17(1H,s).
IR (film) cm: 1749,1668,1605,1504,1264,1148,1021,968, 924,753,693.

Example 9

Preparation of 4-ethoxycarbonyl-2-isopropyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0059] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 2-bromopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 86.7%.

Pale yellow needles (chloroform-hexane)

Melting point: 140.6-141.1 DEG C

H-NMR (CDC I 3) delta : 1.42(3H,t,J=7.1Hz), 1.44(6H,d,J=6.6Hz), 3.87(3H,s), 4.44(2H,q,J=7.1Hz), 5.39-5.54(1H,m), 6.99(2H,d,J=9.0Hz), 7.77(2H,d,J=9.0Hz), 8.14(1H,s).

IR (KBr) cm: 1713,1664,1601,1518,1390,1323,1271,1177, 1132,1030,829.

Mass (m/z): 316 (M).

Example 10

Preparation of 4-ethoxycarbonyl-2-isobutyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0061] Potassium carbonate (605 mg, 4.38 mmol) and 1-bromo-2-methylpropane (360 mg, 2.63 mmol) were added to a solution of 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (600 mg, 2.19 mmol) in N,N-dimethylformamide (6 ml), followed by stirring at 80 DEG C for 30 minutes. After inorganic matter was filtered off, the solvent was distilled off under reduced pressure. The residue was separated and purified by chromatography on a silica gel column [silica gel: 15 g, hexane/ethyl acetate (1/1)], whereby the title compound (705 mg, 97.5%) was obtained.

Pale yellow needles (chloroform-hexane)

Melting point: 83.0-83.3 DEG C

H-NMR (CDC I 3) delta : 0.99(6H,d,J=6.8Hz), 1.42(3H,t,J=7.1Hz), 2.29-2.45(1H,m), 3.87(3H,s), 4.11(2H,d,J=7.3Hz), 4.44(2H,q,J=7.1Hz), 6.99(2H,d,J=8.9Hz), 7.75(2H,d,J=8.9Hz), 8.17(1H,s).

IR (KBr) cm: 1717,1709,1665,1599,1518,1388,1333,1271, 1177,1159,1113,1019,829.

Mass (m/z): 330 (M).

Example 11

Preparation of 6-(3,4-dimethoxyphenyl)-2-isobutyl-4-methoxycarbonyl-2H-pyridazin-3-one

[0063] Using 6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and 1-bromo-2-methylpropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 86.6%.

Yellow needles (chloroform-hexane)

Melting point: 104.2-105.5 DEG C

H-NMR (CDC I 3) delta : 1.00(6H,d,J=6.8Hz), 2.29-2.45(1H,m), 3.94(3H,s), 3.98(3H,s), 4.02(3H,s), 4.13(2H,d,J=7.3Hz), 6.94(2H,d,J=8.6Hz), 7.33(1H,dd,J=2.2,8.6Hz), 7.38(1H,d,J=2.2Hz), 8.23(1H,s).

IR (KBr) cm: 1710,1665,1522,1429,1423,1297,1248,1228, 1177,1112,1026.

Mass (m/z): 346 (M).

Example 12

Preparation of 6-(3-fluoro-4-methoxyphenyl)-2-isobutyl-4-methoxycarbonyl-2H-pyridazin-3-one

[0065] Using 6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and 1-bromo-2-methylpropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 69.9%.

Yellow needles (chloroform-hexane)

Melting point: 119.3-121.3 DEG C

H-NMR (CDC I 3) delta : 0.99(6H,d,J=6.6Hz), 2.37-2.44(1H,m), 3.95(3H,s), 3.98(3H,s), 4.11(2H,d,J=7.3Hz), 6.99-7.07(1H,m), 7.47-7.53(1H,m), 7.57-7.64(1H,m), 8.23(1H,s).

IR (KBr) cm: 1746,1660,1522,1434,1290,1195,1178,1136, 1099,1013.

Example 13

Preparation of 6-(3-chloro-4-methoxyphenyl)-2-isobutyl-4-methoxycarbonyl-2H-pyridazin-3-one

[0067] Using 6-(3-chloro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and 1-bromo-2-methylpropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 79.5%.

Yellow needles (chloroform-hexane)

Melting point: 108.2-109.4 DEG C

H-NMR (CDC I 3) delta : 0.99(6H,d,J=6.6Hz), 2.29-2.45(1H,m), 3.97(3H,s), 3.98(3H,s), 4.12(2H,d,J=7.3Hz), 7.01(1H,d,J=8.8Hz), 7.67(1H,dd,J=2.2,8.8Hz), 7.86(1H,d,J=2.2Hz), 8.19(1H,s).

IR (KBr) cm: 1713,1663,1603,1510,1293.

Mass (m/Z): 352 (M), 350 (M).

Example 14

Preparation of 2-isobutyl-4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0069] Using 4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and 1-bromo-2-methylpropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 77.3%.

Yellow needles (chloroform-hexane)

Melting point: 90.4-91.4 DEG C

¹H-NMR (CDCl₃) delta : 0.99(6H,d,J=6.6Hz), 2.29-2.42(1H,m), 2.53(3H,s), 3.98(3H,s), 4.12(2H,d,J=7.3Hz), 7.32(2H,d,J=8.8Hz), 7.73(2H,d,J=8.8Hz), 8.23(1H,s).

IR (KBr) cm: 1714,1672,1601,1502,1268,1251.

Mass (m/z): 332 (M).

Example 15

Preparation of 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one

[0071] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 1-bromo-3-methyl-2-butene as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 87.6%.

Oil

¹H-NMR (CDCl₃) delta : 1.42(3H,t,J=7.1Hz), 1.75(3H,s), 1.86(3H,s), 3.86(3H,s), 4.44(2H,q,J=7.1Hz), 4.87(2H,d,J=7.1Hz), 5.43-5.52(1H,m), 6.99(2H,d,J=8.9Hz), 7.75(2H,d,J=8.9Hz), 8.16(1H,s).

IR (KBr) cm: 1745,1713,1668,1609,1519,1309,1260,1181, 1134,1022,835.

Mass (m/z): 342 (M).

Example 16

Preparation of 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0073] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and (chloromethyl)cyclopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 89.6%.

Pale yellow needles (chloroform-hexane)

Melting point; 80.1-80.9 DEG C

¹H-NMR (CDCl₃) delta : 0.46-0.59(4H,m), 1.40-1.51(4H,m), 3.87(3H,s), 4.14(2H,d,J=7.3Hz), 4.44(2H,q,J=7.1Hz), 6.99(2H,d,J=9.0Hz), 7.75(2H,d,J=9.0Hz), 7.47-7.51(2H,m), 8.18(1H,s).

IR (KBr) cm: 1715,1706,1664,1598,1389,1273,1128,1114, 1020,828.

Mass (m/z): 328 (M).

Example 17

Preparation of 2-cyclopropylmethyl-6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one

[0075] Using 6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and (chloromethyl) cyclopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 78.7%.

Yellow needles (chloroform-hexane)

Melting point: 136.5-137.3 DEG C

¹H-NMR (CDCl₃) delta : 0.46-0.62(4H,m), 1.39-1.52(1H,m), 3.94(3H,s), 3.97(3H,s), 3.99(3H,s), 4.16(2H,d,J=7.3Hz), 6.94(1H,d,J=8.3Hz), 7.33(1H,dd,J=2.2,8.3Hz), 7.39(1H,d,J=2.2Hz), 8.23(1H,s).

IR (KBr) cm: 1709,1664,1525,1431,1300,1248,1229,1176, 1120,1026,1020.

Mass (m/z): 344 (M).

Example 18

Preparation of 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one

[0077] Using 6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and (chloromethyl) cyclopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 54.7%.

Yellow needles (chloroform-hexane)

Melting point: 113.6-116.6 DEG C

¹H-NMR (CDCl₃) delta : 0.44-0.62(4H,m), 1.37-1.52(1H,m), 3.95(3H,s), 3.98(3H,s), 4.14(2H,d,J=7.3Hz), 7.00-7.07(1H,m), 7.48-7.53(1H,m), 7.58-7.64(1H,m), 8.21(1H,s).

IR (KBr) cm: 1721,1660,1521,1437,1295,1275,1258,1106, 1023.

Example 19

Preparation of 6-(3-chloro-4-methoxyphenyl)-2-cyclopropylmethyl-4-methoxycarbonyl-2H-pyridazin-3-one

[0079] Using 6-(3-chloro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and (chloromethyl) cyclopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 72.7%. Pale yellow needles (chloroform-hexane)

Melting point: 101.4-103.8 DEG C

¹H-NMR (CDCl₃) delta : 0.45-0.62(4H,m), 1.48-1.52(1H,m), 3.97(3H,s), 3.99(3H,s), 4.15(2H,d,J=4.5Hz), 7.01(1H,d,J=8.5Hz), 7.66(1H,dd,J=2.4,8.5Hz), 7.87(1H,d,J=2.4Hz), 8.21(1H,s).

IR (KBr) cm: 1718,1660,1602,1509,1293.

Mass (m/z): 350 (M), 348 (M).

Example 20

Preparation of 2-cyclopropylmethyl-4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0081] Using 4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and (chloromethyl) cyclopropane as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 61.5%.

Yellow needles (chloroform-hexane)

Melting point: 100.2-101.8 DEG C

¹H-NMR (CDCl₃) delta : 0.41-0.61(4H,m), 1.38-1.51(1H,m), 2.53(3H,s), 3.98(3H,s), 4.15(2H,d,J=7.3Hz), 7.32(2H,d,J=8.4Hz), 7.73(2H,d,J=8.4Hz), 8.24(1H,s).

IR (KBr) cm: 1713,1668,1602,1328,1267,1249.

Mass (m/z): 330 (M).

Example 21

Preparation of 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0083] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and cyclopentylmethyl methanesulfonate as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 88.5%.

Pale yellow needles (chloroform-hexane)

Melting point: 63.6-64.4 DEG C

¹H-NMR (CDCl₃) delta : 1.26-1.46(5H,m), 1.49-1.81(6H,,m), 2.50-2.66(1H,m), 3.87(3H,s), 4.23(2H,d,J=7.6Hz), 4.44(2H,q,J=7.1Hz), 6.99(2H,d,J=8.8Hz), 7.75(2H,d,J=8.8Hz), 8.17(1H,s).

IR (KBr) cm: 1708,1667,1601,1518,1388,1272,1178, 1130,1114,1027,827,794.

Mass (m/z): 356 (M).

Example 22

Preparation of 2-benzyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0085] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and benzyl bromide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 96.9%.

Pale yellow crystals

¹H-NMR (CDCl₃) δ : 3.86(3H,s), 3.96(3H,s), 5.43(2H,s), 6.98(2H,d,J=9.1Hz), 7.28-7.37(3H,m), 7.47-7.55(2H,m), 7.75(2H,d,J=9.1Hz), 8.22(1H,s).
Mass (m/z): 350 (M).

Example 23

Preparation of 2-benzyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0087] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and benzyl bromide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 75.3%.

Pale yellow crystals

¹H-NMR (CDCl₃) δ : 1.41(3H,t,J=7.1Hz), 3.86(3H,s), 4.42(2H,q,J=7.1Hz), 5.43(2H,s), 6.98(2H,d,J=9.0Hz), 7.26-7.36(3H,m), 7.50-7.55(2H,m), 7.75(2H,d,J=9.0Hz), 8.17(1H,s).

Example 24

Preparation of 2-(2,4-dichlorobenzyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0089] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 2,4-dichlorobenzyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 88.3%.

Yellow needles (chloroform-hexane)

Melting point: 135.7-136.3 DEG C
¹H-NMR (CDCl₃) δ : 1.42(3H,t,J=7.1Hz), 3.86(3H,s), 4.44(2H,q,J=7.1Hz), 5.54(2H,s), 6.98(2H,d,J=8.9Hz), 7.20(1H,dd,J=2.2,8.3Hz), 7.29(1H,d,J=8.3Hz), 7.43(1H,d,J=2.2Hz), 7.71(2H,d,J=8.9Hz), 8.22(1H,s).
IR (KBr) cm: 1748,1719,1664,1608,1518,1311,1254, 1242,1163,1136,1026,836.
Mass (m/z): 436 (M), 434 (M), 432 (M).

Example 25

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(4-nitrobenzyl)-2H-pyridazin-3-one

[0091] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 4-nitrobenzyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 92.6%.

Yellow fine needles (chloroform-hexane)

Melting point: 215.4-216.6 DEG C

H-NMR (CDC I 3) delta : 3.87(3H,s), 3.97(3H,s), 5.50(2H,s), 7.00(2H,d,J=9.0Hz), 7.67(2H,d,J=8.8Hz), 7.74(2H,d,J=9.0Hz), 8.20(2H,d,J=8.8Hz), 8.26(1H,s).

IR (KBr) cm: 1720,1663,1601,1522,1347,1255.

Mass (m/z): 395 (M).

Example 26

Preparation of 2-(4-aminobenzyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0093] To a solution of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(4-nitrobenzyl)-2H-pyridazin-3-one (100 mg, 0.25 mmol) in methanol (30 m l), 10% palladium on charcoal (40 mg) was added, followed by catalytic reduction at room temperature under atmospheric pressure. Thirty minutes later, the catalyst was filtered off. The methanol was distilled off under reduced pressure. The residue was crystallized from chloroform-diethyl etherhexane, whereby the title compound (91 mg, 98.5%) was obtained as yellow fine needles.

Melting point: 160.0-161.9 DEG C

H-NMR (CDC I 3) delta : 3.65(2H,br), 3.87(3H,s), 3.95(3H,s), 5.31(2H,s), 6.63(2H,d,J=8.4Hz), 6.98(2H,d,J=8.8Hz), 7.36(2H,d,J=8.4Hz), 7.75(2H,d,J=8.8Hz), 8.19(1H,s).

IR (KBr) cm: 3417,3331,1741,1646,1611,1595,1517,1286, 1256,1181.

Mass (m/z): 365 (M).

Example 27

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-[4-(3-pyridylcarbonylamino)benzyl]-2H-pyridazin-3-one

[0094] To a suspension of nicotinic acid (38 mg, 0.31 mmol) in tetrahydrofuran (2 m l), N-[3-(dimethylamino)-propyl]-N'-ethylcarbodiimide.hydrochloride (WSC.HC I) (60 mg,0.31 mmol) was added at room temperature, followed by stirring for 5 minutes. A solution of 2-(4-aminobenzyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (76 mg, 0.21 mmol) in tetrahydrofuran (2 m l) was then added, followed by stirring at the same temperature for 13 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in chloroform (30 m l). The solution was washed successively with water (30 m l) and a saturated aqueous solution of sodium chloride (brine) (30 m l), and was then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure. The residue was separated and purified by silica gel preparative chromatography [developer: chloroform/methanol (10/1)], followed by crystallization from chloroform-hexane. The title compound (78 mg, 79.7%) was obtained as yellow prisms.

Melting point: 235.7-236.9 DEG C (dec.)

H-NMR (CDC I 3) delta : 3.37(3H,s), 3.92(3H,s), 5.42(2H,s), 7.00(2H,d,J=9.0Hz), 7.40-7.46(1H,m), 7.56(2H,d,J=8.5Hz), 7.63(2H,d,J=8.5Hz), 7.76(2H,d,J=9.0Hz), 8.07(1H,br), 8.19-8.25(2H,m), 8.75-8.78(1H,m), 8.99-9.12(1H,s).

IR (KBr) cm: 3303,3266,1740,1668,1640,1606,1542,1518, 1412,1321,1253.
Mass (m/z): 470 (M).

Example 28

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(3-pyridylmethyl)-2H-pyridazin-3-one

[0095] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 3-(chloromethyl)pyridine hydrochloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 38.5%.

Pale yellow needles (chloroform-ether-hexane)

Melting point: 112.3-115.3 DEG C (dec.)
H-NMR (CDC I 3) delta : 3.87(3H,s), 3.97(3H,s), 5.44(2H,s), 6.99(2H,d,J=9.0Hz), 7.24-7.30(1H,m), 7.74(2H,d,J=9.0Hz), 7.86-7.92(1H,m), 8.24(1H,s), 8.54-8.57(1H,m), 7.98-8.81(1H,m).
IR (KBr) cm: 1720,1665,1599,1518,1311,1270.
Mass (m/z): 351 (M).

Example 29

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one

[0097] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 3-phenylpropyl bromide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 94.0%.

Yellow oil

H-NMR (CDC I 3) delta : 1.42(3H,t,J=7.1Hz), 2.17-2.30(2H,m), 2.74(2H,t,J=7.8Hz), 3.86(3H,s), 4.33(2H,t,J=7.1Hz), 4.44(2H,q,J=7.1Hz), 6.98(2H,d,J=8.9Hz), 7.13-7.30(5H,m), 7.74(2H,d,J=8.9Hz), 8.14(1H,s).
IR (film) cm: 1744,1713,1664,1610,1519,1256,1180, 1131,1021.
Mass (m/z): 392 (M).
HRMS: Calcd. for C₂₃H₂₄N₂O₄ (Found): 392.17358 (392.17107).

Example 30

Preparation of 2-cinnamyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0099] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and cinnamyl bromide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound

was obtained in a yield of 92.1%.

Pale yellow oil

¹H-NMR (CDCl₃) δ : 1.42(3H,t,J=7.1Hz), 3.86(3H,s), 4.45(2H,q,J=7.1Hz), 5.03(2H,d,J=6.6Hz), 6.46(1H,td,J=6.6,15.9Hz), 6.75(1H,d,J=15.9Hz), 6.99(2H,d,J=9.0Hz), 7.20-7.41(5H,m), 7.76(2H,d,J=9.0Hz), 8.19(1H,s).
IR (film) cm: 1744,1713,1668,1609,1518,1309,1256, 1025,835.

Example 31

Preparation of 2-(4-chlorocinnamyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0101] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 4-chlorocinnamyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 85.7%.

Yellow needles (chloroform-hexane)

Melting point: 127.0-127.9 DEG C
¹H-NMR (CDCl₃) δ : 1.42(3H,t,J=7.1Hz), 3.87(3H,s), 4.45(2H,q,J=7.1Hz), 5.02(2H,td,J=1.0,6.6Hz), 6.42(1H,td,J=6.6,15.9Hz), 6.69(1H,td,J=1.0,15.9Hz), 6.99(2H,d,J=8.9Hz), 7.26(2H,d,J=8.9Hz), 7.32(2H,d,J=8.9Hz), 7.76(2H,d,J=8.9Hz), 8.20(1H,s).
IR (KBr) cm: 1705,1662,1601,1520,1492,1388,1309,1263, 1181,1149,1026,1015,831.
Mass (m/z): 426 (M), 424 (M).

Example 32

Preparation of 2-(4-chlorocinnamyl)-6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one

Melting point: 117.5-118.7 DEG C
¹H-NMR (CDCl₃) δ : 3.94(3H,s), 3.95(3H,s), 3.99(3H,s), 5.03(2H,dd,J=1.0,6.6Hz), 6.43(1H,td,J=6.6,15.9Hz), 6.70(1H,td,J=1.0,15.9Hz), 6.94(1H,d,J=8.3Hz), 7.27(2H,d,J=8.8Hz), 7.31(2H,d,J=8.8Hz), 7.33(1H,dd,J=2.2,8.3Hz), 7.38(1H,d,J=2.2Hz), 8.26(1H,s).
IR (KBr) cm: 3046,1704,1674,1516,1419,1247,1226, 1151,1023,979.
Mass (m/z): 442 (M), 440 (M).

Example 33

Preparation of 2-(4-chlorocinnamyl)-6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one

[0104] Using 6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and 4-chlorocinnamyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 73.5%.

Pale yellow needles (chloroform-hexane)

Melting point: 131.3-132.3 DEG C

¹H-NMR (CDCl₃) delta : 3.95(3H,s), 3.99(3H,s), 5.02(2H,dd,J=1.1,6.7Hz), 6.42(1H,td,J=6.7,15.9Hz), 6.70(1H,td,J=1.1,15.9Hz), 7.00-7.07(1H,m), 7.28(2H,d,J=8.9Hz), 7.31(2H,d,J=8.9Hz), 7.48-7.53(1H,m), 7.59-7.66(1H,m), 8.22(1H,s).

IR (KBr) cm: 1725,1661,1654,1523,1319,1271,1129.

Mass (m/z): 430 (M), 428 (M).

Example 34

Preparation of 2-(4-chlorocinnamyl)-6-(3-chloro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one

[0106] Using 6-(3-chloro-4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one and 4-chlorocinnamyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 76.8%.

Yellow prisms (chloroform-hexane)

Melting point: 179.7-181.6 DEG C

¹H-NMR (CDCl₃) delta : 3.97(3H,s), 3.99(3H,s), 5.02(2H,dd,J=1.1,6.7Hz), 6.42(1H,td,J=6.7,15.9Hz), 6.71(1H,td,J=1.1,15.9Hz), 7.01(1H,d,J=8.6Hz), 7.28(2H,d,J=8.8Hz), 7.31(2H,d,J=8.8Hz), 7.66(1H,dd,J=2.2,8.6Hz), 7.88(1H,d,J=2.2Hz), 8.22(1H,s).

IR (KBr) cm: 1747,1652,1605,1508,1286,1260,1240.

Mass (m/z): 446 (M), 444 (M).

Example 35

Preparation of 2-(4-chlorocinnamyl)-4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0108] Using 4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and 4-chlorocinnamyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 82.3%.

Yellow prisms (chloroform-hexane)

Melting point: 123.3-126.2 DEG C

¹H-NMR (CDCl₃) δ : 2.53(3H,s), 3.98(3H,s), 5.03(2H,dd,J=1.1,6.7Hz), 6.43(1H,td,J=6.7,15.9Hz), 6.70(1H,td,J=1.1,15.9Hz), 7.27(2H,d,J=8.8Hz), 7.30(2H,d,J=8.8Hz), 7.32(2H,d,J=8.7Hz), 7.73(2H,d,J=8.7Hz), 8.26(1H,s).

IR (KBr) cm: 1712,1666,1600,1502,1490,1270,1095,977.

Mass (m/z): 428 (M), 426 (M).

Example 36

Preparation of 2-(2,4-difluorocinnamyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0110] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 2,4-difluorocinnamyl chloride as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 92.0%.

Yellow oil

¹H-NMR (CDCl₃) δ : 1.42(3H,t,J=7.1Hz), 3.87(3H,s), 4.45(2H,q,J=7.1Hz), 5.04(2H,dd,J=1.0,6.6Hz), 6.48(1H,dd,J=6.6,16.0Hz), 6.73-6.87(3H,m), 6.99(2H,d,J=8.9Hz), 7.37-7.47(1H,m), 7.76(2H,d,J=8.9Hz), 8.20(1H,s).

IR (film) cm: 3074,1745,1713,1668,1610,1519,1503, 1258,1141,1026,967.

Mass (m/z): 426 (M).

HRMS: Calcd. for C₂₃H₂₀F₂N₂O₄ (Found): 426.13908 (426.14058).

Example 37

Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-[4-(methylthio)phenylcarbamoylmethyl]-2H-pyridazin-3-one

(1) Preparation of 2-bromo-4'-(methylthio)acetanilide

[0112] To a solution of 4-(methylthio)aniline (200 mg, 1.44 mmol) in chloroform (2 mL), a saturated aqueous solution of sodium hydrogencarbonate (2 mL) was added, followed by the dropwise addition of a solution of bromoacetyl bromide (300 mg, 1.49 mmol) in chloroform (2 mL) under ice cooling. The mixture was then stirred for 1 hour. The chloroform layer was separated, washed successively with 2N hydrochloric acid (10 mL) and brine (10 mL), and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, whereby the title compound (356 mg, 95.3%) was obtained as pale brown crystals.

(2) Preparation of 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-[4-(methylthio)phenylcarbamoylmethyl]-2H-pyridazin-3-one

[0113] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 2-bromo-4'-(methylthio)acetanilide as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 90.0%.

Yellow prisms (chloroform-hexane)

Melting point: 130.2-132.4 DEG C

H-NMR (CDC I 3) delta : 2.44(3H,s), 3.87(3H,s), 3.98(3H,s), 5.08(2H,s), 6.98(2H,d,J=8.9Hz), 7.19(2H,d,J=8.7Hz), 7.46(2H,d,J=8.7Hz), 7.78(2H,d,J=8.9Hz), 8.32(1H,s), 8.64(1H,br).

IR (KBr) cm: 3273,1744,1702,1652,1598,1518,1250.

Mass (m/z): 439 (M).

Example 38

Preparation of 2-benzyl-4-carbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0115] To 2-benzyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (73 mg, 0.20 mmol), an ammonia-methanol solution (about 10% W/W, 3 m l) was added, followed by stirring at room temperature for 17 hours. Precipitated crystals were collected by filtration, whereby the title compound (59 mg, 90.7%) was obtained as colorless fine needles.

Melting point: 196.0-198.0 DEG C

H-NMR (CDC I 3) delta : 3.87(3H,s), 5.48(2H,s), 5.93(1H,brs), 6.99(2H,d,J=9.0Hz), 7.30-7.40(3H,m), 7.49(2H,dd,J=2.0,8.1Hz), 7.83(2H,d,J=9.0Hz), 8.67(1H,s), 9.41(1H,br).

IR (KBr) cm: 3157,1703,1518,1391,1255,1034,830,729.

Example 39

Preparation of 4-carbamoyl-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0116] Using 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 38 were repeated likewise, whereby the title compound was obtained in a yield of 90.5%.

Slightly yellow prisms (methanol-diethyl ether)

Melting point: 182.2-183.3 DEG C

H-NMR (CDC I 3) delta : 0.47-0.62(4H,m), 1.40-1.51(1H,m), 3.87(3H,s), 4.19(2H,d,J=7.3Hz), 5.95(1H,br), 7.00(2H,d,J=8.8Hz), 7.82(2H,d,J=8.8Hz), 8.68(1H,s), 9.50(1H,br).

IR (KBr) cm: 3322,3161,1694,1610,1519,1419,1386,1269, 1252,1184,1024, 839.

Mass (m/z): 299 (M).

Example 40

Preparation of 4-carbamoyl-2-cyclopentylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0118] Using 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a

starting material, the procedures of Example 38 were repeated likewise, whereby the title compound was obtained in a yield of 91.5%.

Colorless needles (chloroform-hexane)

Melting point: 182.2-183.3 DEG C

¹H-NMR (CDCl₃) delta : 1.31-1.46(2H,m), 1.50-1.83(6H,m), 2.48-2.65(1H,m), 3.87(3H,s), 4.28(2H,d,J=7.6Hz), 5.94(1H,br), 7.00(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.67(1H,s), 9.51(1H,br).

IR (KBr) cm: 3350,3158,1701,1517,1457,1389,1254,1189, 1177, 1131,1033,828,799.

Mass (m/z): 327 (M).

Example 41

Preparation of 4-carbamoyl-2-cinnamyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0120] Using 2-cinnamyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 38 were repeated likewise, whereby the title compound was obtained in a yield of 40.0%.

Colorless fine needles (chloroform-diethyl ether)

Melting point: 184.0-186.0 DEG C

¹H-NMR (CDCl₃) delta : 3.87(3H,s), 5.08(2H,dd,J=1.0,6.6Hz), 5.93(1H,brs), 6.44(1H,td,J=6.6,15.9Hz), 6.75(1H,td,J=1.0,15.9Hz), 6.99(2H,d,J=8.9Hz), 7.24-7.43(5H,m), 7.83(2H,d,J=9.0Hz), 8.69(1H,s), 9.44(1H,br).

IR (KBr) cm: 3347,3148,1704,1633,1610,1517,1391,1254, 1034,829.

Example 42

Preparation of 4-carbamyl-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0122] Using 2-(4-chlorocinnamyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 38 were repeated likewise, whereby the title compound was obtained in a yield of 96.6%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 195.1-195.5 DEG C

¹H-NMR (CDCl₃) delta : 3.87(3H,s), 5.07(2H,td,J=1.0,6.6Hz), 5.98(1H,br), 6.42(1H,td,J=6.6,15.8Hz), 6.69(1H,td,J=1.0,15.8Hz), 6.99(2H,d,J=8.9Hz), 7.27(2H,d,J=8.6Hz), 7.33(2H,d,J=8.6Hz), 7.83(2H,d,J=8.9Hz), 8.69(1H,s), 9.43(1H,br).

IR (KBr) cm: 3324,3142,1702,1611,1570,1518,1491, 1388,1257,1169,1034,831.

Mass (m/z): 397 (M), 395 (M).

Example 43

Preparation of 2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0124] To 4-ethoxycarbonyl-2-isobutyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (40 mg, 0.13 mmol), a 30% methylamine-ethanol (2 ml) was added, followed by stirring at room temperature for 30 minutes. The solvent was distilled off under reduced pressure and the residue was crystallized from chloroform-hexane, whereby the title compound (35 mg, 91.9%) was obtained as colorless needles.

Melting point: 124.9-125.2 DEG C

¹H-NMR (CDCl₃) delta : 1.00(6H,d,J=6.6Hz), 2.37-2.44(1H,m), 3.02(3H,d,J=5.3Hz), 3.87(3H,s), 4.15(2H,d,J=7.3Hz), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.67(1H,s), 9.72(1H,br).

IR (KBr) cm: 3244, 1686, 1590, 1253, 1184, 1026, 834.

Mass (m/z): 315 (M).

Example 44

Preparation of 6-(4-methoxyphenyl)-2-methyl-4-methylcarbamoyl-2H-pyridazin-3-one

[0125] Using 2-methoxycarbonyl-6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 95.3%.

Slightly yellow needles (chloroform-hexane)

Melting point: 150.5-150.7 DEG C

¹H-NMR (CDCl₃) delta : 3.03(3H,d,J=5.0Hz), 3.87(3H,s), 3.95(3H,s), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.68(1H,s), 9.67(1H,br).

IR (KBr) cm: 3248, 1679, 1625, 1610, 1517, 1459, 1284, 1249, 1185, 1004, 838.

Example 45

Preparation of 2-ethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0127] Using 2-ethyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 82.8%.

Slightly yellow needles (chloroform-hexane)

Melting point: 122.4-122.9 DEG C

H-NMR (CDC I 3) delta : 1.50(3H,t,J=7.3Hz), 3.03(3H,d,J=5.0Hz), 3.87(3H,s), 4.38(2H,q,J=7.3Hz), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.67(1H,s), 9.72(1H,br).
 IR (KBr) cm: 3241,1674,1567,1553,1517,1415,1251,1183, 1025.
 Mass (m/z): 287 (M).

Example 46

Preparation of 2-cyanomethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0129] Using 2-cyanomethyl-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 82.8%.

Pale brown prisms (chloroform-hexane)

Melting point: 153.4-154.9 DEG C
 H-NMR (CDC I 3) delta : 3.04(3H,t,J=5.3Hz), 3.88(3H,s), 5.16(2H,s), 7.01(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.74(1H,s), 9.28(1H,br).
 IR (KBr) cm: 3292,2261,1690,1679,1554,1517,1257.
 Mass (m/z): 298 (M).

Example 47

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-methylcarbamoylmethyl-2H-pyridazin-3-one

(1) Preparation of 4-ethoxycarbonyl-2-ethoxycarbonylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0131] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and ethyl bromoacetate as starting materials, the procedures of Example 1 were repeated likewise, whereby the title compound was obtained in a yield of 84.5%.

Pale yellow needles (chloroform-diethyl ether-hexane)

Melting point: 77.1-77.8 DEG C
 H-NMR (CDC I 3) delta : 1.29(3H,t,J=7.1Hz), 1.41(3H,t,J=7.1Hz), 3.86(3H,s), 4.26(2H,q,J=7.1Hz), 4.43(2H,q,J=7.1Hz), 4.99(2H,s), 6.98(2H,d,J=8.9Hz), 7.73(2H,d,J=8.9Hz), 8.25(1H,s).
 IR (KBr) cm: 1754,1718,1675,1607,1518,1313,1284,1264, 1217,1159,1030,1018,842,794.
 Mass (m/z): 360 (M).

(2) Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-methylcarbamoylmethyl-2H-pyridazin-3-one

[0133] Using 4-ethoxycarbonyl-2-ethoxycarbonylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 84.5%.

Colorless fine needles

Melting point: 250.1-250.8 DEG C

¹H-NMR (CDC l 3) delta : 2.87(3H,d,J=4.6Hz), 2.99(3H,d,J=5.0Hz), 3.87(3H,s), 4.95(2H,s), 6.14(2H,br), 6.98(2H,d,J=9.1Hz), 7.82(2H,d,J=9.1Hz), 8.70(1H,s), 9.44(1H,br).

IR (KBr) cm: 3293,3114,1683,1666,1516,1252,1164,1026, 834,798.

Mass (m/z): 330 (M).

Example 48

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-vinyl-2H-pyridazin-3-one

[0135] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-vinyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 36.7%.

Yellow needles (chloroform-hexane)

Melting point: 130.3-132.8 DEG C

¹H-NMR (CDC l 3) delta : 3.03(3H,d,J=5.0Hz), 3.88(3H,s), 5.18(1H,d,J=8.6Hz), 6.03(1H,d,J=15.4Hz), 7.01(2H,d,J=9.0Hz), 7.85(1H,dd,J=8.6,15.4Hz), 7.89(2H,d,J=9.0Hz), 8.70(1H,s), 9.50(1H,br).

IR (KBr) cm: 3238,3121,1683,1632,1607,1548,1516,1411, 1314,1272,1245,1180.

Example 49

Preparation of 2-(2-hydroxyethyl)-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0137] Using 4-ethoxycarbonyl-2-(2-hydroxyethyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 97.2%.

Pale yellow needles (chloroform-hexane)

Melting point: 160.3-160.6 DEG C

¹H-NMR (CDC l 3) delta : 2.87(1H,brt,J=5.7Hz), 3.00(3H,d,J=5.1Hz), 3.87(3H,s), 4.17-4.19(2H,m), 4.51-4.56(2H,m), 7.00(2H,d,J=8.9Hz), 7.80(2H,d,J=8.9Hz), 8.69(1H,s), 9.57(1H,br).

IR (KBr) cm: 3462,3228,1671,1619,1592,1536,1519,1265, 1187,1070,833.

Mass (m/z): 303 (M).

Example 50

Preparation of 2-(2-cyanoethyl)-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0139] Using 2-(2-cyanoethyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 90.3%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 164.5-167.2 DEG C (dec.)

¹H-NMR (CDCl₃) delta : 2.99(2H,t,J=6.7Hz), 3.03(3H,d,J=5.0Hz), 3.87(3H,s), 4.59(2H,t,J=6.9Hz), 7.00(2H,d,J=8.6Hz), 7.83(2H,d,J=8.6Hz), 8.71(1H,s), 9.44(1H,br).

IR (KBr) cm: 2246,1717,1664,1520,1275,1250.

Mass (m/z): 312 (M).

Example 51

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-n-propyl-2H-pyridazin-3-one

[0141] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-n-propyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 85.3%.

Colorless needles (chloroform-hexane)

Melting point: 106.5-107.1 DEG C

¹H-NMR (CDCl₃) delta : 1.02(3H,t,J=7.3Hz), 1.85-2.00(2H,m), 3.02(3H,d,J=5.0Hz), 3.87(3H,s), 4.29(2H,t,J=7.3Hz), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.66(1H,s), 9.72(1H,br).

IR (KBr) cm: 3266,1690,1549,1517,1248,1185,1027.

Mass (m/z): 301 (M).

Example 52

Preparation of 2-isopropyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0143] Using 4-ethoxycarbonyl-2-isopropyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 91.9%.

Colorless needles (chloroform-hexane)

Melting point: 154.0-154.3 DEG C

¹H-NMR (CDCl₃) delta : 1.47(6H,d,J=6.6Hz), 3.03(3H,d,J=5.0Hz), 3.87(3H,s), 5.36-5.52(1H,m), 7.00(2H,d,J=8.9Hz), 7.85(2H,d,J=8.9Hz), 8.66(1H,s), 9.77(1H,br).

IR (KBr) cm: 3262,1677,1547,1518,1417,1310,1269,1250, 1175,1021,831,801.

Mass (m/z): 301 (M).

Example 53

Preparation of 6-(3,4-dimethoxyphenyl)-2-isobutyl-4-methylcarbamoyl-2H-pyridazin-3-one

[0145] Using 4-ethoxycarbonyl-6-(3,4-dimethoxyphenyl)-2-isobutyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 92.8%.

Slightly yellow needles (chloroform-hexane)

Melting point: 111.4-112.6 DEG C

¹H-NMR (CDCl₃) delta : 1.01(6H,d,J=6.6Hz), 2.28-2.43(1H,m), 3.03(3H,d,J=5.0Hz), 3.95(3H,s), 3.97(3H,s), 4.16(2H,d,J=7.3Hz), 6.96(1H,d,J=8.6Hz), 7.41-7.46(2H,m), 8.68(1H,s), 9.72(1H,br).

IR (KBr) cm: 3276,1683,1585,1551,1512,1257,1227,1171, 1118,1021,871.

Mass (m/z): 345 (M).

Example 54

Preparation of 6-(3-fluoro-4-methoxyphenyl)-2-isobutyl-4-methylcarbamoyl-2H-pyridazin-3-one

[0147] Using 6-(3-fluoro-4-methoxyphenyl)-2-isobutyl-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 88.3%.

Pale yellow needles (chloroform-hexane)

Melting point: 153.3-154.9 DEG C

¹H-NMR (CDCl₃) delta : 1.00(6H,d,J=6.6Hz), 2.27-2.43(1H,m), 3.02(3H,d,J=5.0Hz), 3.95(3H,s), 4.15(2H,d,J=7.3Hz), 7.00-7.08(1H,m), 7.55-7.61(1H,m), 7.65-7.72(1H,m), 9.68(1H,br).

IR (KBr) cm: 3248,1684,1522,1509,1435,1297,1276.

Mass (m/z): 333 (M).

Example 55

Preparation of 6-(3-chloro-4-methoxyphenyl)-2-isobutyl-4-methylcarbamoyl-2H-pyridazin-3-one

[0149] Using 6-(3-chloro-4-methoxyphenyl)-2-isobutyl-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 94.3%.

Slightly yellow needles (chloroform-hexane)

Melting point: 181.8-183.5 DEG C

¹H-NMR (CDC l 3) delta : 1.00(6H,d,J=6.6Hz), 2.27-2.43(1H,m), 3.02(3H,d,J=5.0Hz), 3.97(3H,s), 4.15(2H,d,J=7.3Hz), 7.01(1H,d,J=8.6Hz), 7.72(1H,dd,J=2.3,8.6Hz), 7.85(1H,d,J=2.3Hz), 8.64(1H,s), 9.68(1H,br).

IR (KBr) cm: 3248,1685,1546,1509,1410,1294,1264.

Mass (m/z): 351 (M), 349 (M).

Example 56

Preparation of 2-isobutyl-4-methylcarbamoyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0151] Using 2-isobutyl-4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 92.3%.

Slightly yellow needles (chloroform-hexane)

Melting point: 129.6-130.6 DEG C

¹H-NMR (CDC l 3) delta : 1.00(6H,d,J=6.6Hz), 2.27-2.43(1H,m), 2.53(3H,s), 3.02(3H,d,J=4.9Hz), 4.16(2H,d,J=7.3Hz), 7.33(2H,d,J=8.7Hz), 7.80(2H,d,J=8.7Hz), 8.68(1H,s), 9.69(1H,br).

IR (KBr) cm: 3275,1687,1624,1575,1506,1400,1394.

Mass (m/z): 331 (M).

Example 57

Preparation of 6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0153] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 79.0%.

Slightly yellow needles (chloroform-hexane)

Melting point: 103.6-104.0 DEG C

H-NMR (CDC I 3) delta : 1.77(3H,s), 1.88(3H,s), 3.02(3H,d,J=5.0Hz), 3.87(3H,s), 4.90(2H,d,J=7.3Hz), 5.41-5.50(1H,m), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.66(1H,s), 9.71(1H,br).

IR (KBr) cm: 3244,1675,1546,1517,1248,1175,1025,831, 798.

Mass (m/z): 327 (M).

Example 58

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-(2-pyridylmethyl)carbamoylmethyl-2H-pyridazin-3-one

(1) Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0155] Using 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 97.9%.

Colorless needles (chloroform-hexane)

Melting point: 246.5-246.9 DEG C

H-NMR (CDC I 3) delta : 3.06(3H,d,J=5.0Hz), 3.87(3H,s), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.74(1H,s), 9.46(1H,br), 11.89(1H,br).

IR (KBr) cm: 3219,3142,1675,1568,1518,1257,1226,1184, 1032,832.

Mass (m/z): 259 (M).

(2) Preparation of 2-ethoxycarbonylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0157] Using 6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one as a starting material, the procedures of Example 47-(1) were repeated likewise, whereby the title compound was obtained in a yield of 98.5%.

Melting point: 141.0-142.2 DEG C

H-NMR (CDC I 3) delta : 1.31(3H,t,J=7.3Hz), 3.01(3H,d,J=5.0Hz), 3.87(3H,s), 4.28(2H,q,J=7.3Hz), 5.02(2H,s), 6.99(2H,d,J=8.9Hz), 7.81(2H,d,J=8.9Hz), 8.72(1H,s), 9.47(1H,br).

IR (KBr) cm: 3283,1735,1691,1508,1259,1226,1169,1028.

Mass (m/z): 345 (M).

(3) Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-(2-pyridylmethyl)carbamoylmethyl-2H-pyridazin-3-one

[0158] In xylene, 2-ethoxycarbonylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one and 2-(aminomethyl)pyridine were refluxed at 150 DEG C for 7 hours. Post-treatments were conducted as in Example 47-(2), whereby the title compound was obtained in a yield of 44.5%.

Slightly yellow prisms (chloroform-hexane)

Melting point: 194.7-195.8 DEG C

¹H-NMR (CDCl₃) delta : 3.00(3H,t,J=5.0Hz), 3.87(3H,s), 4.62(2H,d,J=5.0Hz), 5.06(2H,s), 6.98(2H,d,J=8.9Hz), 7.15-7.21(1H,m), 7.33-7.38(1H,m), 7.35(1H,brt,J=5.0Hz), 7.61-7.69(1H,m), 7.83(2H,d,J=8.9Hz), 8.43-8.47(1H,m), 8.72(1H,s), 9.49(1H,br).

IR (KBr) cm: 3283,1681,1664,1518,1251,1167,1024.

Mass (m/z): 407 (M).

Example 59

Preparation of 2-(2-hydroxyethyl)carbamoylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0160] In methanol, 2-ethoxycarbonylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one and 2-aminoethanol were heated under reflux for 4 hours. Post-treatments were conducted as in Example 43, whereby the title compound was obtained in a yield of 91.0%.

Colorless fine needles (chloroform-hexane)

Melting point: 240.2-241.2 DEG C

¹H-NMR (CDCl₃) delta : 2.34(1H,t,J=5.7Hz), 2.98(3H,d,J=5.1Hz), 3.46-3.53(2H,m), 3.72-3.80(2H,m), 3.87(3H,s), 4.98(2H,s), 6.52(1H,br), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.70(1H,s), 9.42(1H,br).

IR (KBr) cm: 3405,3288,1675,1657,1574,1554,1519,1508, 1416,1402,1253,1074,835.

Mass (m/z): 360 (M).

Example 60

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-[4-(methylthio)phenylcarbamoylmethyl]-2H-pyridazin-3-one

[0162] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-[4-(methylthio)phenylcarbamoylmethyl]-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 92.2%.

Slightly yellow prisms (chloroform-hexane)

Melting point: 230.6-232.0 DEG C

¹H-NMR (CDCl₃) delta : 2.46(3H,s), 3.03(3H,d,J=5.0Hz), 3.87(3H,s), 3.98(3H,s), 5.10(2H,s), 6.99(2H,d,J=9.1Hz), 7.23(2H,d,J=8.7Hz), 7.46(2H,d,J=8.7Hz), 7.84(2H,d,J=9.1Hz), 8.16(1H,br), 8.74(1H,s), 9.42(1H,br).

IR (KBr) cm: 3290,3236,1680,1539,1518,1254.

Mass (m/z): 438 (M).

Example 61

Preparation of 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0164] Using 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 89.1%.

Slightly yellow needles (methanol-diethyl ether)

Melting point: 136.6-137.5 DEG C

¹H-NMR (CDCl₃) delta : 0.47-0.62(4H,m), 1.39-1.49(1H,m), 3.03(3H,d,J=5.1Hz), 3.87(3H,s), 4.18(2H,d,J=7.3Hz), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.67(1H,s), 9.72(1H,brd,J=5.1Hz).

IR (KBr) cm: 3339,1684,1627,1609,1518,1252,1183,1027, 845,836,811.

Mass (m/z): 313 (M).

Example 62

Preparation of 2-cyclopropylmethyl-6-(3,4-dimethoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0166] Using 2-cyclopropylmethyl-6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 95.3%.

Pale yellow needles (chloroform-hexane)

Melting point: 156.1-154.1 DEG C

¹H-NMR (CDCl₃) delta : 0.47-0.65(4H,m), 1.38-1.51(1H,m), 3.03(3H,d,J=5.0Hz), 3.95(3H,s), 3.97(3H,s), 4.19(2H,d,J=7.3Hz), 6.96(1H,d,J=8.9Hz), 7.43(1H,d,J=2.3Hz), 7.44(1H,dd,J=2.3,8.9Hz), 8.69(1H,s), 9.72(1H,br).

IR (KBr) cm: 3267,1686,1552,1520,1508,1422,1255,1232, 1034.

Mass (m/z): 343 (M).

Example 63

Preparation of 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0168] Using 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 90.3%.

Pale yellow needles (chloroform-hexane)

Melting point: 139.6-140.7 DEG C

¹H-NMR (CDCl₃) delta : 0.45-0.64(4H,m), 1.36-1.51(1H,m), 3.03(3H,d,J=5.0Hz), 3.96(3H,s), 4.18(2H,d,J=7.3Hz), 7.01-7.08(1H,m), 7.56-7.61(1H,m), 7.65-7.72(1H,m), 8.66(1H,s), 9.69(1H,br).

IR (KBr) cm: 3281,1688,1523,1510,1436,1299,1275.

Mass (m/z): 331 (M).

Example 64

Preparation of 6-(3-chloro-4-methoxyphenyl)-2-cyclopropylmethyl-4-methylcarbamoyl-2H-pyridazin-3-one

[0170] Using 6-(3-chloro-4-methoxyphenyl)-2-cyclopropylmethyl-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 90.3%.

Slightly yellow needles (chloroform-hexane)

Melting point: 172.4-173.4 DEG C

¹H-NMR (CDCl₃) delta : 0.46-0.64(4H,m), 1.38-1.50(1H,m), 3.03(3H,d,J=5.3Hz), 3.97(3H,s), 4.18(2H,d,J=7.3Hz), 7.02(1H,d,J=8.8Hz), 7.73(1H,dd,J=2.3,8.8Hz), 7.95(1H,d,J=2.3Hz), 8.65(1H,s), 9.68(1H,br).

IR (KBr) cm: 3244,1684,1552,1509,1410,1294,1264.

Mass (m/z): 349 (M), 347 (M).

Example 65

Preparation of 2-cyclopropylmethyl-4-methylcarbamoyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0172] Using 2-cyclopropylmethyl-4-methoxycarbonyl-6-[4-(methylthiophenyl)]-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 94.3%.

Yellow prisms (chloroform-hexane)

Melting point: 116.5-118.0 DEG C

¹H-NMR (CDCl₃) delta : 0.45-0.64(4H,m), 1.36-1.51(1H,m), 2.53(3H,s), 3.03(3H,d,J=4.9Hz), 4.18(2H,d,J=7.3Hz), 7.33(2H,d,J=8.7Hz), 7.80(2H,d,J=8.7Hz), 8.69(1H,s), 9.69(1H,br).

IR (KBr) cm: 3275,1686,1625,1595,1545,1505,1400.

Mass (m/z): 329 (M).

Example 66

Preparation of 2-cyclopropylmethyl-4-ethylcarbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0174] In methanol, 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 70% aqueous solution of ethylamine were reacted at 70 DEG C for 4 hours. Post-treatments were conducted as in Example 43, whereby the title compound was obtained in a yield of 80.2%.

Colorless needles (chloroform-hexane)

Melting point: 136.3-136.9 DEG C

¹H-NMR (CDC l 3) delta : 0.47-0.64(4H,m), 1.28(3H,t,J=7.3Hz), 1.37-1.53(1H,m), 3.51(2H,d,J=8.9Hz), 3.87(3H,s), 4.18(2H,d,J=7.3Hz), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.68(1H,s), 9.76(1H,brt,J=5.9Hz).

IR (KBr) cm: 3211,1679,1622,1610,1517,1417,1249,1182, 1033,834.

Mass (m/z): 327 (M).

Example 67

Preparation of 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-n-propylcarbamoyl-2H-pyridazin-3-one

[0176] Using 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and an n-propylaminemethanol solution as starting materials, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 65.4%.

Colorless needles (chloroform-hexane)

Melting point: 101.3-101.6 DEG C

¹H-NMR (CDC l 3) delta : 0.46-0.63(4H,m), 1.01(3H,t,J=7.3Hz), 1.39-1.52(1H,m), 1.60-1.76(2H,m), 3.44(2H,d,J=6.9Hz), 3.87(3H,s), 4.18(2H,d,J=7.3Hz), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.68(1H,s), 9.81(1H,br).

IR (KBr) cm: 3216,1679,1622,1608,1517,1416,1252,1182, 1033,833.

Mass (m/z): 341 (M).

Example 68

Preparation of 4-benzylcarbamoyl-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0178] Benzylamine (318 mg, 2.97 mmol) was added to a solution of 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (65 mg, 0.20 mmol) in xylene (1 m l), followed by stirring at 140 DEG C for 24 hours. The reaction mixture was added with ethyl acetate (20 m l), washed successively with 2N hydrochloric acid (20 m l) and brine (20 m l), and then dried over anhydrous sodium sulfate. The solvent was distilled off and the residue (98 mg) was crystallized from chloroform-hexane, whereby the title compound (72 mg, 93.4%) was obtained as pale yellow fine needles.

Melting point: 119.7-120.1 DEG C

¹H-NMR (CDC I 3) delta : 0.44-0.62(4H,m), 1.37-1.50(1H,m), 3.89(3H,s), 4.16(2H,d,J=7.3Hz), 4.67(2H,d,J=5.9Hz), 7.00(2H,d,J=8.8Hz), 7.24-7.41(5H,m), 7.83(2H,d,J=8.8Hz), 8.71(1H,s), 10.18(1H,brt,J=5.9Hz).

IR (KBr) cm: 3210,1675,1622,1610,1516,1274,1250,1185, 1028,838.

Mass (m/z): 389 (M).

Example 69

Preparation of 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-(2-pyridylmethyl)carbamoyl-2H-pyridazin-3-one

[0179] In xylene, 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and 2-(aminomethyl)pyridine were reacted at 140 DEG C for 1 hour. Post-treatments were conducted as in Example 58-(3), whereby the title compound was obtained in a yield of 84.2%.

Slightly yellow needles (chloroform-hexane)

Melting point: 98.6-99.3 DEG C

¹H-NMR (CDC I 3) delta : 0.46-0.63(4H,m), 1.39-1.55(1H,m), 3.87(3H,s), 4.20(2H,d,J=7.3Hz), 4.83(2H,d,J=5.4Hz), 7.00(2H,d,J=9.3Hz), 7.17-7.23(1H,m), 7.32-7.37(1H,m), 7.63-7.71(1H,m), 7.83(2H,d,J=9.3Hz), 8.61-8.65(1H,m), 8.71(1H,s), 10.55(1H,brt,J=5.4Hz).

IR (KBr) cm: 3252,1683,1624,1609,1516,1417,1273,1253, 1181,1022,834.

Mass (m/z): 390 (M).

Example 70

Preparation of 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-(4-pyridyl)carbamoyl-2H-pyridazin-3-one

[0181] Sodium hydride (9 mg, 0.38 mmol; used after removal of oil by washing it with toluene) was added to a solution of 4-aminopyridine (34 mg, 0.361 mmol) in dimethylsulfoxide (0.5 m l), followed by stirring at room temperature for 15 minutes. Thereafter, 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (80 mg, 0.24 mmol) was added, followed by stirring at the same temperature for 30 minutes. The reaction mixture was added with ethyl acetate (30 m l), washed successively with water (20 m l) and brine (20 m l); and then dried over anhydrous sodium sulfate. The solvent was distilled off and the residue (61 mg) was separated and purified by silica gel preparative chromatography [developer: chloroform/methanol (10/1)], whereby the title compound (61 mg, 61.1%) was obtained.

Pale yellow fine needles (chloroform-hexane)

Melting point: 181.3-181.5 DEG C

¹H-NMR (CDC I 3) delta : 0.49-0.68(4H,m), 1.40-1.56(1H,m), 3.89(3H,s), 4.24(2H,d,J=7.3Hz), 7.02(2H,d,J=8.9Hz), 7.69(2H,d,J=6.3Hz), 7.85(2H,d,J=8.9Hz), 8.57(2H,d,J=6.3Hz), 8.75(1H,s), 12.25(1H,br).

IR (KBr) cm: 1697,1629,1607,1517,1273,1254,1184,1017, 835, 813,805,791.

Mass (m/z): 376 (M).

Example 71

Preparation of 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-phenylcarbamoyl-2H-pyridazin-3-one

[0183] 2-Cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and aniline were processed as in Example 70, whereby the title compound was obtained in a yield of 12.2%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 162.8-163.3 DEG C

H-NMR (CDC I 3) delta : 0.49-0.67(4H,m), 1.41-1.68(1H,m), 3.88(3H,s), 4.23(2H,d,J=7.3Hz), 7.01(2H,d,J=8.9Hz), 7.13-7.20(1H,m), 7.34-7.42(2H,m), 7.75-7.81(2H,m), 7.85(2H,d,J=8.9Hz), 8.77(1H,s), 12.00(1H,br).

IR (KBr) cm: 3189,1687,1602,1518,1274,1254,1184,1025, 834,804,791.

Mass (m/z): 375 (M).

Example 72

Preparation of 2-cyclopentylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0185] Using 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 75.2%.

Colorless needles (chloroform-hexane)

Melting point: 107.4-107.8 DEG C

H-NMR (CDC I 3) delta : 1.30-1.45(2H,m), 1.50-1.82(6H,m), 2.47-2.64(1H,m), 3.02(3H,d,J=5.0Hz), 3.87(3H,s), 4.27(2H,d,J=7.6Hz), 7.00(2H,d,J=8.9Hz), 7.83(2H,d,J=8.9Hz), 8.66(1H,s), 9.74(1H,br).

IR (KBr) cm: 3218,1679,1624,1611,1560,1550,1517,1414, 1249,1188,1138,1030,844,802.

Mass (m/z): 341 (M).

Example 73

Preparation of 2-cyclopentylmethyl-4-ethylcarbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0187] In methanol, 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and a 70% aqueous solution of ethylamine were processed as in Example 43, whereby the title compound was obtained in a yield of 82.2%.

Colorless needles (chloroform-hexane)

Melting point: 129.1-129.4 DEG C

H-NMR (CDC I 3) delta : 1.27(3H,t,J=7.3Hz), 1.34-1.45(2H,m), 1.50-1.82(6H,m), 2.48-2.65(1H,m), 3.44-3.56(2H,m), 3.87(3H,s), 4.27(2H,d,J=7.6Hz), 6.99(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.67(1H,s), 9.76(1H,br).

IR (KBr) cm: 3242,1683,1623,1609,1518,1417,1311,1249, 1181,1033,834,800.

Mass (m/z): 355 (M).

Example 74

Preparation of 2-cyclopentylmethyl-6-(4-methoxyphenyl)-4-n-propylcarbamoyl-2H-pyridazin-3-one

[0189] Using 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 67 were repeated likewise, whereby the title compound was obtained in a yield of 79.1%.

Colorless needles (chloroform-hexane)

Melting point: 109.9-110.2 DEG C

H-NMR (CDC I 3) delta : 1.01(3H,t,J=7.3Hz), 1.31-1.46(2H,m), 1.50-1.83(8H,m), 2.48-2.65(1H,m), 3.44(2H,q,J=6.4Hz), 3.87(3H,s), 4.27(2H,d,J=7.6Hz), 7.00(2H,d,J=8.9Hz), 7.82(2H,d,J=8.9Hz), 8.67(1H,s), 9.81(1H,br).

IR (KBr) cm: 3246,1683,1544,1519,1417,1311,1273,1252, 1030,835,797.

Mass (m/z): 369 (M).

Example 75

Preparation of 4-benzylcarbamoyl-2-cyclopentylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0191] In xylene, 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one and benzylamine were reacted at 140 DEG C for 2 hours. Post-treatments were conducted as in Example 68, whereby the title compound was obtained in a yield of 78.5%.

Pale yellow needles (chloroform-hexane)

Melting point: 107.6-108.1 DEG C

H-NMR (CDC I 3) delta : 1.28-1.44(2H,m), 1.48-1.81(6H,m), 2.46-2.63(1H,m), 3.87(3H,s), 4.25(2H,d,J=7.6Hz), 4.66(2H,d,J=5.9Hz), 7.00(2H,d,J=8.9Hz), 7.23-7.40(5H,m), 7.82(2H,d,J=8.9Hz), 8.70(1H,s), 10.18(1H,brt,J=5.9Hz).

IR (KBr) cm: 3251,1677,1624,1611,1517,1386,1259,1179, 1136,1033,831.

Mass (m/z): 417 (M).

Example 76

Preparation of 2-cyclopentylmethyl-6-(4-methoxyphenyl)-4-(2-pyridylmethyl)carbamoyl-2H-pyridazin-3-one

[0193] Using 2-cyclopentylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 58-(3) were repeated likewise, whereby the title compound was obtained in a yield of 88.6%.

Colorless needles (chloroform-hexane)

Melting point: 126.6-127.5 DEG C

¹H-NMR (CDC l 3) delta : 1.30-1.46(2H,m), 1.49-1.82(6H,m), 2.50-2.67(1H,m), 3.87(3H,s), 4.29(2H,d,J=7.6Hz), 4.82(2H,d,J=5.3Hz), 7.00(2H,d,J=8.9Hz), 7.16-7.23(1H,m), 7.31-7.36(1H,m), 7.62-7.70(1H,m), 7.83(2H,d,J=8.9Hz), 8.60-8.64(1H,m), 8.69(1H,s), 10.53(1H,brt,J=5.3Hz).

IR (KBr) cm: 3255,1673,1624,1610,1511,1457,1433,1259, 1251,1028,832.

Mass (m/z): 418 (M).

Example 77

Preparation of 4-benzylcarbamoyl-6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one

[0195] In xylene, 4-ethoxycarbonyl-6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one and benzylamine were reacted at 140 DEG C for 1 hour. Post-treatments were conducted as in Example 68, whereby the title compound was obtained in a yield of 94.2%.

Pale yellow needles (chloroform-hexane)

Melting point: 144.8-145.8 DEG C

¹H-NMR (CDC l 3) delta : 3.87(3H,s), 3.94(3H,s), 4.67(2H,d,J=5.9Hz), 7.00(2H,d,J=8.9Hz), 7.23-7.40(5H,m), 7.82(2H,d,J=8.9Hz), 8.71(1H,s), 10.13(1H,brt,J=5.9Hz).

IR (KBr) cm: 3244,1679,1624,1583,1516,1455,1251,1182, 1030,836.

Mass (m/z): 349 (M).

Example 78

Preparation of 6-(4-methoxyphenyl)-2-methyl-4-(2-pyridylmethyl)carbamoyl-2H-pyridazin-3-one

[0197] Using 4-ethoxycarbonyl-2-methyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 58-(3) were repeated likewise, whereby the title compound was obtained in a yield of 86.1%.

Pale yellow needles (chloroform-hexane)

Melting point: 122.4-122.9 DEG C

¹H-NMR (CDCl₃) δ : 3.87(3H,s), 3.97(3H,s), 4.82(2H,d,J=5.6Hz), 7.00(2H,d,J=8.9Hz), 7.17-7.23(1H,m), 7.31-7.36(1H,m), 7.63-7.71(1H,m), 7.82(2H,d,J=8.9Hz), 8.61-8.65(1H,m), 8.71(1H,s), 10.53(1H,brt,J=5.6Hz).

IR (KBr) cm: 3238,1683,1625,1613,1516,1435,1248,1180, 1035,836.

Mass (m/z): 350 (M).

Example 79

Preparation of 2-benzyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one and 2-benzyl-4-dimethylcarbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0199] To 40% aqueous solution of dimethylamine (3 ml), 2-benzyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (71 mg, 0.19 mmol) was added, followed by stirring at room temperature for 17 hours. The solvent was distilled off, and the residue (74 mg) was separated and purified by silica gel preparative chromatography [developer: chloroform/methanol (20/1)]. From fractions of large R_f values, the title compound [2-benzyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one] (29.4 mg, 44.7%) was obtained.

Pale yellow needles (chloroform-diethyl ether)

Melting point: 181.7-182.1 DEG C

¹H-NMR (CDCl₃) δ : 3.00(3H,d,J=4.9Hz), 3.87(3H,s), 5.47(2H,s), 7.00(2H,d,J=8.8Hz), 7.30-7.36(2H,m), 7.47(2H,d,J=6.4Hz), 7.84(2H,d,J=9.3Hz), 8.67(1H,s), 9.65(1H,br).

IR (KBr) cm: 3270,1680,1607,1518,1408,1251,1026,850, 743.

[0201] From fractions of small R_f values, the title compound [2-benzyl-6-(4-methoxyphenyl)-4-(dimethylcarbamoyl)-2H-pyridazin-3-one] (10.5 mg, 14.8%) was also obtained.

Colorless fine needles (chloroform-diethyl etherhexane)

Melting point: 183.0-184.0 DEG C

¹H-NMR (CDCl₃) δ : 2.96(3H,s), 3.11(3H,s), 3.86(3H,s), 5.41(2H,s), 6.97(2H,d,J=9.0Hz), 7.26-7.33(3H,m), 7.50(2H,dd,J=2.0,8.0Hz), 7.72(2H,d,J=9.0Hz), 7.74(1H,s).

IR (KBr) cm: 1654,1641,1610,1521,1250,1025,832.

Example 80

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-(4-nitrobenzyl)-2H-pyridazin-3-one

[0203] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(4-nitrobenzyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 92.2%.

Yellow needles (chloroform-hexane)

Melting point: 198.8-199.4 DEG C

¹H-NMR (CDC l 3) delta : 3.01(3H,d,J=5.0Hz), 3.88(3H,s), 5.54(2H,s), 7.01(2H,d,J=9.2Hz), 7.62(2H,d,J=8.9Hz), 7.82(2H,d,J=9.2Hz), 8.22(2H,d,J=8.9Hz), 8.71(1H,s), 9.48(1H,br).

IR (KBr) cm: 3282,1680,1515,1344,1254.

Mass (m/z): 394 (M).

Example 81

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-[4-(3-pyridylcarbonylamino)benzyl]-2H-pyridazin-3-one

[0205] Using 4-methoxycarbonyl-4-methylcarbamoyl-2-[4-(3-pyridylcarbonylamino)benzyl]-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 92.7%.

Slightly yellow fine needles (chloroform-hexane)

Melting point: 226.7-227.6 DEG C (dec.)

¹H-NMR (CDC l 3) delta : 3.00(3H,d,J=5.0Hz), 3.87(3H,s), 5.46(2H,s), 7.00(2H,d,J=9.0Hz), 7.44(1H,ddd,J=1.1,4.6,6.8Hz), 7.53(2H,d,J=8.5Hz), 7.63(2H,d,J=8.5Hz), 7.83(2H,d,J=9.0Hz), 7.87(1H,br), 8.19(2H,ddd,J=1.6,1.7,8.1Hz), 8.66(1H,s), 8.78(1H,dd,J=1.7,4.6Hz), 9.08(1H,dd,J=1.1,1.6Hz), 9.62(1H,brg,J=5.0Hz).

IR (KBr) cm: 3339,1679,1601,1535,1515,1412,1317,1253.

Mass (m/z): 469 (M).

Example 82

Preparation of 2-(2,4-dichlorobenzyl)-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0207] Using 2-(2,4-dichlorobenzyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 97.4%.

Fine pale yellow needles (chloroform-hexane)

Melting point: 154.2-156.2 DEG C

¹H-NMR (CDC l 3) delta : 3.01(3H,d,J=5.0Hz), 3.86(3H,s), 5.57(2H,s), 6.98(2H,d,J=8.9Hz), 7.16

(1H,d,J=8.3Hz), 7.22(1H,dd,J=2.0,8.3Hz), 7.45(1H,d,J=2.0Hz), 7.79(2H,d,J=8.9Hz), 8.72(1H,s), 9.54(1H,br).
 IR (KBr) cm: 3288,1683,1629,1610,1592,1474,1516,1411, 1255,1165,834.
 Mass (m/z): 421 (M), 419 (M), 417 (M).

Example 83

Preparation of 6-(4-methoxyphenyl)-4-methylcarbamoyl-2-(3-pyridylmethyl)-2H-pyridazin-3-one

[0209] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(3-pyridylmethyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 87.7%.

Slightly yellow needles (chloroform-hexane)

Melting point: 153.8-154.3 DEG C (dec.)
 H-NMR (CDCI₃) delta : 3.01(3H,d,J=5.0Hz), 3.87(3H,s), 5.47(2H,s), 7.00(2H,d,J=9.1Hz), 7.25-7.32(1H,m), 7.78-7.85(3H,m), 8.56-8.59(1H,m), 8.67(1H,s), 8.77-8.80(1H,m), 9.55(1H,br).
 IR (KBr) cm: 3253,1679,1547,1518,1417,1316,1251,1028, 833,796.
 Mass (m/z): 350 (M).

Example 84

Preparation of 2-cinnamyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0211] Using 2-cinnamyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 100%.

Pale yellow prisms (chloroform-diethyl ether-hexane)

Melting point: 160.0-161.0 DEG C
 H-NMR (CDCI₃) delta : 3.02(3H,d,J=5.1Hz), 3.86(3H,s), 5.07(2H,dd,J=1.2,6.6Hz), 6.43(1H,td,J=6.6,15.8Hz), 6.73(1H,d,J=15.9Hz), 6.99(2H,d,J=8.8Hz), 7.27(2H,d,J=8.6Hz), 7.23-7.34(3H,m), 7.40(2H,dd,J=1.2,8.1Hz), 7.83(2H,d,J=9.0Hz), 8.68(1H,s), 9.66(1H,brs).
 IR (KBr) cm: 3245,1686,1611,1516,1024,835.

Example 85

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0213] Using 2-(4-chlorocinnamyl)-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a

starting material, the procedures of Example 43 were repeated likewise, whereby the title compound was obtained in a yield of 93.3%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 184.2-185.4 DEG C

H-NMR (CDC I 3) delta : 3.03(3H,d,J=4.6Hz), 3.87(3H,s), 5.06(2H,d,J=6.6Hz), 6.40(1H,td,J=6.6,15.8Hz), 6.67(1H,d,J=15.8Hz), 7.00(2H,d,J=8.6Hz), 7.27(2H,d,J=8.6Hz), 7.33(2H,d,J=8.6Hz), 7.84(2H,d,J=8.6Hz), 8.69(1H,s), 9.63(1H,brd,J=4.6Hz).
IR (KBr) cm: 3246,1677,1550,1519,1491,1402,1260,1186, 1158, 1029,841.
Mass (m/z): 411 (M), 409 (M).

Example 86

Preparation of 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0215] To a suspension of 2-(4-chlorocinnamyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (1.35 g, 3.29 mmol) in methanol (50 ml), a 4N aqueous solution of sodium hydroxide (20 ml) was added at room temperature, followed by stirring at the same temperature for 30 minutes. The methanol was distilled off under reduced pressure, and water (100 ml) was added to the residue. The mixture was acidified with hydrochloric acid under ice-water cooling, followed by extraction with chloroform. The organic layer was washed with brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, whereby the title compound (1.30 g, 99.7%) was obtained as yellow crystals.

Melting point: 222.6-224.0 DEG C (dec.)

H-NMR (CDC I 3) delta : 3.88(3H,s), 5.10(2H,d,J=6.8Hz), 6.40(1H,td,J=6.8,15.6Hz), 6.74(1H,d,J=15.6Hz), 7.01(2H,d,J=8.8Hz), 7.34(2H,d,J=8.8Hz), 7.81(2H,d,J=8.8Hz), 8.65(1H,s), 14.10(1H,brd).
IR (KBr) cm: 1743,1630,1609,1561,1518,1475,1420,1252, 1029,900,837,814.
Mass (m/z): 398 (M), 396 (M).

Example 87

Preparation of 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0216] To a suspension of 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (657 mg, 1.66 mmol) in benzene (15 ml), triethylamine (168 mg, 1.66 mmol) and diphenylphosphoryl azide (456 mg, 1.66 mmol) were added at room temperature. The mixture was stirred at the same temperature for 30 minutes and then heated under reflux at 100 DEG C for 30 minutes. Ethanol (20 ml) was then added to the reaction mixture, followed by heating under reflux at 100 DEG C for 15 hours. The solvent was distilled off under reduced pressure, and the residue was separated and purified by chromatography on a silica gel column [silica gel: 50 g, hexane/ethyl acetate (3/1)]. Crystallization was conducted from chloroform-hexane, whereby the title compound (327 mg, 44.9%) was obtained as slightly yellow fine needles.

Melting point: 171.2-172.1 DEG C

H-NMR (CDC I 3) delta : 1.34(3H,t,J=7.1Hz), 3.86(3H,s), 4.28(2H,q,J=7.1Hz), 4.99(2H,dd,J=1.0,6.3Hz), 6.40(1H,td,J=6.3,15.9Hz), 6.65(1H,td,J=1.0,15.9Hz), 6.96(2H,d,J=8.8Hz), 7.26(2H,d,J=8.6Hz), 7.31(2H,d,J=8.6Hz), 7.78(2H,d,J=8.8Hz), 8.08(1H,brs), 8.26(1H,s).
IR (KBr) cm: 3224,1727,1642,1606,1540,1518,1491,1256, 1225,1177,830.

Mass (m/z): 441 (M), 439 (M).

Example 88

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-isopropoxycarbonylamino-2H-pyridazin-3-one

[0217] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise in isopropyl alcohol, whereby the title compound was obtained in a yield of 41.4%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 123.9-127.4 DEG C

¹H-NMR (CDCl₃) delta : 1.33(6H,d,J=6.4Hz), 3.86(3H,s), 4.97-5.10(3H,m), 6.40(1H,td,J=6.4,15.9Hz), 6.64(1H,td,J=1.2,15.9Hz), 6.96(2H,d,J=8.9Hz), 7.29(2H,d,J=8.9Hz), 7.30(2H,d,J=8.9Hz), 7.30(2H,d,J=8.9Hz), 7.79(2H,d,J=8.9Hz), 8.03(1H,brs), 8.26(1H,s).

IR (KBr) cm: 3370,3056,1732,1645,1613,1535,1518,1497, 1256,1178,1111,832.

Mass (m/z): 455 (M), 453 (M).

Example 89

Preparation of 4-n-butoxycarbonylamino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0219] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise in n-butanol, whereby the title compound was obtained in a yield of 37.3%.

Pale yellow needles (chloroform-hexane)

Melting point: 150.2-150.9 DEG C

¹H-NMR (CDCl₃) delta : 0.96(3H,t,J=7.4Hz), 1.35-1.50(2H,m), 1.63-1.75(2H,m), 3.86(3H,s), 4.23(2H,t,J=6.6Hz), 4.99(2H,dd,J=1.2,6.4Hz), 6.40(1H,td,J=6.4,15.8Hz), 6.64(1H,td,J=1.2,15.8Hz), 6.96(2H,d,J=8.9Hz), 7.27(2H,d,J=8.9Hz), 7.30(2H,d,J=8.9Hz), 7.78(2H,d,J=8.9Hz), 8.08(1H,brs), 8.26(1H,s).

IR (KBr) cm: 3223,3031,1728,1641,1606,1541,1516,1491, 1247,1220,1181.

Mass (m/z): 469 (M), 467 (M).

Example 90

Preparation of 4-benzyloxycarbonylamino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0221] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise in benzyl alcohol, whereby the title compound was obtained in a yield of 12.1%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 190.5-191.7 DEG C

¹H-NMR (CDCl₃) delta : 3.85(3H,s), 4.98(2H,dd,J=1.0,6.4Hz), 5.25(2H,s), 6.39(1H,td,J=6.4,15.9Hz), 6.63(1H,td,J=1.0,15.9Hz), 6.96(2H,d,J=9.0Hz), 7.29(2H,d,J=8.8Hz), 7.30(2H,d,J=8.8Hz), 7.32-7.44 (5H,m), 7.77(2H,d,J=9.0Hz), 8.17(1H,brs), 8.26(1H,s).

IR (KBr) cm: 3231,3034,1729,1640,1607,1540,1516,1252, 1223,1210.

Mass (m/z): 503 (M), 501 (M).

Example 91

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-[4-(methylthio)benzyloxycarbonylamino]-2H-pyridazin-3-one

[0223] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise in 4-(methylthio)benzyl alcohol, whereby the title compound was obtained in a yield of 46.0%.

Slightly yellow fine needles (chloroform-hexane)

Melting point: 187.6-188.7 DEG C

¹H-NMR (CDCl₃) delta : 2.49(3H,s), 3.85(3H,s), 4.98(2H,dd,J=1.2,6.4Hz), 5.20(2H,s), 6.39 (1H,td,J=6.4,15.9Hz), 6.42(1H,td,J=1.2,15.9Hz), 6.96(2H,d,J=8.9Hz), 7.23-7.36(8H,m), 7.77 (2H,d,J=8.9Hz), 8.15(1H,brs), 8.24(1H,s).

IR (KBr) cm: 3224,3028,1729,1640,1605,1541,1518,1501, 1491,1252,1176.

Mass (m/z): 549 (M), 547 (M).

Example 92

Preparation of 4-carboxy-6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one

[0225] Using 6-(4-methoxyphenyl)-4-ethoxycarbonyl-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 93.1%.

Pale yellow needles (chloroform-hexane)

Melting point: 153.5-156.6 DEG C

H-NMR (CDC l 3) delta : 1.78(3H,s), 1.88(3H,s), 3.87(3H,s), 4.94(2H,d,J=6.8Hz), 5.38-5.54(1H,m), 7.01(2H,d,J=8.8Hz), 7.80(2H,d,J=8.8Hz), 8.62(1H,s), 14.27(1H,br).
 IR (KBr) cm: 1740,1653,1629,1609,1517,1477,1420,1252, 900.
 Mass (m/z): 314 (M).

Example 93

Preparation of 4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one

[0227] Using 4-carboxy-6-(4-methoxyphenyl)-2-(3-methyl-2-butenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 25.9%.

Pale yellow needles (chloroform-hexane)

Melting point: 130.2-131.2 DEG C

H-NMR (CDC l 3) delta : 1.33(3H,t,J=7.1Hz), 1.75(3H,s), 1.87(3H,s), 3.86(3H,s), 4.27(2H,q,J=7.1Hz), 4.84(2H,d,J=7.1Hz), 5.41-5.50(1H,m), 6.96(2H,d,J=8.8Hz), 7.78(2H,d,J=8.8Hz), 8.09(1H,br), 8.23(1H,s).

IR (KBr) cm: 3216,1722,1644,1605,1539,1518,1255,1225, 1176,1027,832.

Mass (m/z): 357 (M).

Example 94

Preparation of 4-carboxy-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0229] Using 2-cyclopropylmethyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 99.7%.

Yellow crystals

Melting point: 153.9-154.7 DEG C

H-NMR (CDC l 3) delta : 0.50-0.66(4H,m), 1.41-1.51(1H,m), 3.88(3H,s), 4.23(2H,d,J=7.3Hz), 7.02(2H,d,J=8.9Hz), 7.81(2H,d,J=8.9Hz), 8.64(1H,s), 14.31(1H,br).

IR (KBr) cm: 1743,1630,1608,1558,1515,1482,1461,1418.

Example 95

Preparation of 2-cyclopropylmethyl-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0231] Using 4-carboxy-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting

material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 44.2%.

Colorless needles (chloroform-hexane)

Melting point: 119.1-119.6 DEG C

¹H-NMR (CDCl₃) delta : 0.45-0.60(4H,m), 1.32-1.45(4H,m), 3.86(3H,s), 4.11(2H,d,J=7.3Hz), 4.28(2H,q,J=7.1Hz), 6.96(2H,d,J=8.9Hz), 7.79(2H,d,J=8.9Hz), 8.10(1H,br), 8.25(1H,s).

IR (KBr) cm: 3320,1722,1636,1606,1541,1515,1250,1178, 1031,1021,887,836.

Mass (m/z): 343 (M).

Example 96

Preparation of 2-benzyl-4-carboxy-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0233] Using 2-benzyl-4-ethoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 94.8%.

Yellow crystals

¹H-NMR (CDCl₃) delta : 3.88(3H,s), 5.50(2H,s), 7.01(2H,d,J=8.8Hz), 7.30-7.55(5H,m), 7.81(2H,d,J=8.8Hz), 8.62(1H,s), 14.14(1H,br).

IR (KBr) cm: 1750,1633,1607,1516,1472,1457,1419,1250, 1026,898,838.

Mass (m/z): 336 (M).

Example 97

Preparation of 2-benzyl-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0235] Using 2-benzyl-4-carboxy-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 11.2%.

Pale yellow needles (chloroform-diethyl ether)

Melting point: 152.1-162.5 DEG C

¹H-NMR (CDCl₃) delta : 1.33(3H,t,J=7.1Hz), 3.86(3H,s), 4.25(2H,q,J=7.1Hz), 5.40(2H,s), 6.96(2H,d,J=8.9Hz), 7.27-7.38(3H,m), 7.45-7.50(2H,m), 7.78(2H,d,J=8.9Hz), 8.07(1H,brs), 8.24(1H,s).

IR (KBr) cm: 3225,1728,1641,1606,1540,1516,1256,1226, 1180,1171,829.

Mass (m/z): 379 (M).

Example 98

Preparation of 4-carboxy-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one

[0237] Using 4-methoxycarbonyl-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 85.8%.

Pale yellow needles (chloroform-hexane)

Melting point: 121.0-122.1 DEG C

H-NMR (CDC I 3) delta : 2.23-2.36(2H,m), 2.77(2H,t,J=7.3Hz), 3.88(3H,s), 4.41(2H,t,J=7.3Hz), 7.01(2H,d,J=8.8Hz), 7.14-7.30(5H,m), 7.79(2H,d,J=8.8Hz), 8.57(1H,s), 14.21(1H,br).
IR (KBr) cm: 1740,1632,1609,1515,1474,1451,1417,1249, 1187,837.

Example 99

Preparation of 4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one

[0239] Using 4-carboxy-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 41.1%.

Colorless needles (chloroform-diethyl ether-hexane)

Melting point: 100.9-101.3 DEG C

H-NMR (CDC I 3) delta : 1.35(3H,t,J=7.76Hz), 2.16-2.28(2H,m), 2.73(2H,t,J=7.7Hz), 3.86(3H,s), 4.28(2H,q,J=7.1Hz), 4.30(2H,t,J=7.6Hz),6.96(2H,d,J=9.0Hz), 7.14-7.31(5H,m), 7.77(2H,d,J=9.0Hz), 8.08(1H,brs), 8.22(1H,s).
IR (KBr) cm: 3223,1725,1641,1608,1547,1517,1225,1200, 1175.

Example 100

Preparation of 4-benzyloxycarbonylamino-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one

[0241] Using 4-carboxy-6-(4-methoxyphenyl)-2-(3-phenylpropyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 90 were repeated likewise, whereby the title compound was obtained in a yield of 52.8%.

Colorless needles (chloroform-hexane)

Melting point: 117.6-118.1 DEG C (dec.)

¹H-NMR (CDCl₃) delta : 2.15-2.27(2H,m), 2.72(2H,t,J=7.1Hz), 3.86(3H,s), 4.29(2H,t,J=7.1Hz), 5.23(2H,s), 6.36(2H,d,J=8.9Hz), 7.13-7.30(5H,m), 7.32-7.44(5H,m), 7.76(2H,d,J=8.9Hz), 8.16(1H,brs), 8.22(1H,s).

IR (KBr) cm: 3221,1733,1640,1604,1539,1516,1500,1252, 1220,1175.

Example 101

Preparation of 4-carboxy-2-(4-chlorocinnamyl)-6-(3,4-dimethoxyphenyl)-2H-pyridazin-3-one

[0243] Using 2-(4-chlorocinnamyl)-6-(3,4-dimethoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 99.1%.

Yellow fine needles (chloroform-hexane)

Melting point: 229.5-230.9 DEG C (dec.)

¹H-NMR (CDCl₃) delta : 3.95(6H,s), 5.11(2H,dd,J=1.0,6.8Hz), 6.40(1H,td,J=6.8,16.1Hz), 6.75(1H,td,J=1.0,16.1Hz), 6.97(1H,d,J=8.8Hz), 7.33(2H,d,J=8.8Hz), 7.39-7.45(2H,m), 8.67(1H,s), 14.09(1H,brs).

IR (KBr) cm: 1753,1635,1570,1520,1471,1460,1238.

Mass (m/z): 428 (M), 426 (M).

Example 102

Preparation of 2-(4-chlorocinnamyl)-6-(3,4-dimethoxyphenyl)-4-ethoxycarbonylamino-2H-pyridazin-3-one

[0245] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(3,4-dimethoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 43.6%.

Slightly yellow needles (chloroform-hexane)

Melting point: 183.8-184.8 DEG C

¹H-NMR (CDCl₃) delta : 1.35(3H,t,J=7.3Hz), 3.93(3H,s), 3.94(3H,s), 4.29(2H,q,J=7.3Hz), 5.01(2H,dd,J=1.0,6.6Hz), 6.41(1H,td,J=6.3,15.8Hz), 6.65(1H,dt,J=15.8,1.0Hz), 6.92(1H,d,J=8.2Hz), 7.26(2H,d,J=8.6Hz), 7.31(2H,d,J=8.6Hz), 7.37(1H,dd,J=2.2,8.2Hz), 7.42(1H,d,J=2.0Hz), 8.09(1H,br), 8.27(1H,s).

IR (KBr) cm: 3232,3023,1725,1636,1607,1544,1519,1491, 1423,1262,1223,1151,1022.

Mass (m/z): 471 (M), 469 (M).

Example 103

Preparation of 4-carboxy-2-(4-chlorocinnamyl)-6-(3-fluoro-4-methoxyphenyl)-2H-pyridazin-3-one

[0247] Using 2-(4-chlorocinnamyl)-6-(3-fluoro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 96.5%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 215.8-219.2 DEG C

¹H-NMR (CDCl₃) delta : 3.97(3H,s), 5.10(2H,dd,J=1.5,6.8Hz), 6.39(1H,td,J=6.8,16.1Hz), 6.75(1H,td,J=1.5,16.1Hz), 7.03-7.10(1H,m), 7.30(2H,d,J=9.0Hz), 7.33(2H,d,J=9.0Hz), 7.54-7.59(1H,m), 7.66-7.72(1H,m), 8.61(1H,s), 13.99(1H,br).

IR (KBr) cm: 1745,1628,1523,1481,1437,1271.

Mass (m/z): 416 (M), 414 (M).

Example 104

Preparation of 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-(3-fluoro-4-methoxyphenyl)-2H-pyridazin-3-one

[0249] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(3-fluoro-4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 29.4%.

Slightly yellow fine needles (chloroform-hexane)

Melting point: 186.7-187.5 DEG C

¹H-NMR (CDCl₃) delta : 1.35(3H,t,J=7.1Hz), 3.94(3H,s), 4.29(2H,q,J=7.1Hz), 4.99(2H,dd,J=1.2,6.6Hz), 6.39(1H,td,J=6.6,16.1Hz), 6.65(1H,td,J=1.2,16.1Hz), 6.97-7.04(1H,m), 7.27(2H,d,J=8.8Hz), 7.30(2H,d,J=8.8Hz), 7.51-7.56(1H,m), 7.62-7.68(1H,m), 8.08(1H,brs), 8.24(1H,s).

IR (KBr) cm: 3217,1728,1644,1610,1544,1520.

Mass (m/z): 459 (M), 457 (M).

Example 105

Preparation of 4-carboxy-2-(4-chlorocinnamyl)-6-(3-chloro-4-methoxyphenyl)-2H-pyridazin-3-one

[0251] Using 2-(4-chlorocinnamyl)-6-(3-chloro-4-methoxyphenyl)-4-methoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 95.1%.

Pale yellow crystalline powder (chloroform-hexane)

H-NMR (CDCI 3) delta : 3.98(3H,s), 5.11(2H,dd,J=1.0,6.8Hz), 6.39(1H,td,J=6.8,15.6Hz), 6.76(1H,td,J=1.0,15.6Hz), 7.03(1H,d,J=8.6Hz), 7.30(2H,d,J=8.8Hz), 7.33(2H,d,J=8.8Hz), 7.71(1H,dd,J=2.1,8.6Hz), 7.96(1H,d,J=2.1Hz), 8.63(1H,s), 13.99(1H,br).

IR (KBr) cm: 1748,1628,1508,1481,1407,1292,1260.

Mass (m/z): 432 (M), 430 (M).

Example 106

Preparation of 2-(4-chlorocinnamyl)-6-(3-chloro-4-methoxyphenyl)-4-ethoxycarbonylamino-2H-pyridazin-3-one

[0253] Using 4-carboxy-2-(4-chlorocinnamyl)-6-(3-chloro-4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 44.9%.

Colorless fine needles (chloroform-hexane)

Melting point: 183.0-183.8 DEG C

H-NMR (CDCI 3) delta : 1.35(3H,t,J=7.1Hz), 3.95(3H,s), 4.29(2H,q,J=7.1Hz), 4.99(2H,dd,J=1.0,6.6Hz), 6.40(1H,td,J=6.6,15.8Hz), 6.66(1H,dt,J=15.8,1.0Hz), 6.97(1H,d,J=8.6Hz), 7.27(2H,d,J=8.7Hz), 7.31(2H,d,J=8.7Hz), 7.69(1H,dd,J=2.3,8.6Hz), 7.91(1H,d,J=2.3Hz), 8.09(1H,brs), 8.24(1H,s).

IR (KBr) cm: 3235,1724,1641,1606,1540,1508,1264,1229.

Mass (m/z): 475 (M), 473 (M).

Example 107

Preparation of 4-carboxy-2-(4-chlorocinnamyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0255] Using 2-(4-chlorocinnamyl)-4-methoxycarbonyl-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 77.1%.

Yellow prisms (chloroform-hexane)

Melting point: 176.0-177.6 DEG C (dec.)

H-NMR (CDCI 3) delta : 2.54(3H,s), 5.11(2H,d,J=6.8Hz), 6.39(1H,td,J=6.8,15.9Hz), 6.74(1H,d,J=15.9Hz), 7.25-7.37(6H,m), 7.78(2H,d,J=8.8Hz), 8.66(1H,s), 14.01(1H,br).

IR (KBr) cm: 1749,1655,1630,1594,1567,1492,1474,1403.

Mass (m/z): 414 (M), 412 (M).

Example 108

Preparation of 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one

[0257] Using 4-carboxy-2-(4-chlorocinnamyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 13.6%.

Pale yellow fine needles (chloroform-hexane)

Melting point: 158.3-162.1 DEG C

¹H-NMR (CDCl₃) delta : 1.35(3H,t,J=7.1Hz), 2.52(3H,s), 4.29(2H,q,J=7.1Hz), 5.00(2H,dd,J=1.1,6.5Hz), 6.40(1H,td,J=6.5,15.9Hz), 6.65(1H,td,J=1.1,15.9Hz), 7.27(2H,d,J=8.8Hz), 7.30(2H,d,J=8.7Hz), 7.30(2H,d,J=8.8Hz), 7.76(2H,d,J=8.7Hz), 8.13(1H,br), 8.27(1H,s).

IR (KBr) cm: 3220,1728,1641,1606,1538,1501,1491.

Mass (m/z): 457 (M), 455 (M).

Example 109

Preparation of 4-carboxy-2-(2,4-difluorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0259] Using 2-(2,4-difluorocinnamyl)-4-methoxycarbonyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 86 were repeated likewise, whereby the title compound was obtained in a yield of 93.1%.

Slightly yellow fine needles (chloroform-hexane)

Melting point: 200.3-201.3 DEG C

¹H-NMR (CDCl₃) delta : 3.88(3H,s), 5.11(2H,dd,J=1.2,6.8Hz), 6.45(1H,td,J=6.8,16.1Hz), 6.73-6.92(3H,m), 7.01(2H,d,J=8.8Hz), 7.37-7.48(1H,m), 7.82(2H,d,J=8.8Hz), 8.66(1H,s), 14.09(1H,brs).

IR (KBr) cm: 3065,1741,1632,1608,1504,1474,1419,1252, 967.

Mass (m/z): 398 (M).

Example 110

Preparation of 2-(2,4-difluorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0261] Using 4-carboxy-2-(2,4-difluorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 87 were repeated likewise, whereby the title compound was obtained in a yield of 30.0%.

Pale yellow needles (chloroform-hexane)

Melting point: 128.3-128.9 DEG C

H-NMR (CDC l 3) delta : 3.15(3H,t,J=7.1Hz), 3.86(3H,s), 4.28(2H,q,J=7.1Hz), 5.01(2H,dd,J=1.2,6.6Hz), 6.44(1H,td,J=6.6,16.1Hz), 6.73-6.86(3H,m), 6.96(2H,d,J=8.8Hz), 7.36-7.46(1H,m), 7.79(2H,d,J=8.8Hz), 8.08(1H,brs), 8.26(1H,s).

IR (KBr) cm: 3221,3073,1728,1641,1605,1541,1519,1502, 1256,1224,1176.

Mass (m/z): 398(M).

Example 111

Preparation of 4-amino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0263] To a suspension of 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-(4-methoxyphenyl)-2H-pyridazin-3-one (335 mg, 0.76 mmol) in methanol (40 m l), a 4N aqueous solution of sodium hydroxide (20 m l) was added, followed by stirring at 70 DEG C for 30 minutes. The methanol was distilled off. Water (100 m l) was added to the residue, followed by extraction with chloroform. The organic layer was washed with brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was separated and purified by chromatography on a silica gel column (silica gel: 10 g, chloroform). Crystallization was conducted from chloroform-hexane, whereby the title compound (266 mg, 95.0%) was obtained as colorless fine needles.

Melting point: 142.7-143.2 DEG C

H-NMR (CDC l 3) delta : 3.84(3H,s), 4.93-5.01(4H,m), 6.43(1H,td,J=6.4,15.9Hz), 6.64(1H,td,J=1.0,15.9Hz), 6.69(1H,s), 6.95(2H,d,J=8.9Hz), 7.25(2H,d,J=8.6Hz), 7.31(2H,d,J=8.6Hz), 7.69(2H,d,J=8.9Hz).

IR (KBr) cm: 3435,3325,3038,1646,1612,1597,1521,1491, 1252,1238,833.

Mass (m/z): 369 (M), 367 (M).

Example 112

Preparation of 2-(4-chlorocinnamyl)-4-formylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0264] To a solution of 4-amino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (40 mg, 0.11 mmol) in benzene (2 m l), triethylamine (151 mg, 1.49 mmol) and a formic acid-acetic acid (1:1) mixed solution (0.5 m l) were added, followed by stirring at room temperature for 16 hours. The reaction mixture was extracted with chloroform. The extract was washed successively with a saturated solution of sodium hydrogen-carbonate and brine, and was then dried over anhydrous sodium sulfate. The solvent was distilled off and the residue was crystallized from chloroform-hexane; whereby the title compound (41 mg, 95.2%) was obtained as colorless needles.

Melting point: 213.0-213.8 DEG C

H-NMR (CDC l 3) delta : 3.86(3H,s), 5.00(2H,dd,J=1.0,6.5Hz), 6.40(1H,td,J=6.5,15.9Hz), 6.66(1H,td,J=1.0,15.9Hz), 6.97(2H,d,J=9.0Hz), 7.26(2H,d,J=8.8Hz), 7.32(2H,d,J=8.8Hz), 7.79(2H,d,J=9.0Hz), 8.59(1H,s), 8.64(1H,s), 8.79(1H,br).

IR (KBr) cm: 3277,1702,1634,1601,1549,1518,1491,1418, 1245,1138,1033,812.

Mass (m/z): 397 (M), 395 (M).

Example 113

Preparation of 4-acetylamino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0265] Acetic anhydride (0.5 ml) was added to 4-amino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (40 mg, 0.11 mmol), followed by heating under stirring at 70 DEG C for 12 hours. A saturated aqueous solution of sodium hydrogencarbonate was added to the reaction mixture. Subsequent to stirring at room temperature for 1 hour, the mixture was extracted with ethyl acetate. The organic layer was washed with brine and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was separated and purified by silica gel preparative chromatography [developer: hexane/ethyl acetate (1/1)]. Crystallization was conducted from chloroform-hexane, whereby the title compound (31 mg, 70.0%) was obtained as slightly brown needles.

Melting point: 158.7-161.9 DEG C

¹H-NMR (CDCl₃) delta: 2.27(3H,s), 3.86(3H,s), 5.00(2H,dd,J=1.2,6.4Hz), 6.39(1H,td,J=6.5,15.9Hz), 6.65(1H,td,J=1.2,15.9Hz), 6.97(2H,d,J=9.0Hz), 7.27(2H,d,J=8.9Hz), 7.30(2H,d,J=8.9Hz), 7.79(2H,d,J=9.0Hz), 8.58(1H,s), 8.61(1H,brs).

IR (KBr) cm: 3274,3002,1701,1634,1603,1537,1516,1491, 1405,1252,1180,1070.

Mass (m/z): 411 (M), 409 (M).

Example 114

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-propionylamino-2H-pyridazin-3-one

[0266] 4-Amino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one and propionic anhydride were processed as in Example 113, whereby the title compound was obtained in a yield of 84.6%.

Colorless needles (chloroform-hexane)

Melting point: 147.7-148.6 DEG C

¹H-NMR (CDCl₃) delta: 1.26(3H,t,J=7.6Hz), 2.51(2H,q,J=7.6Hz), 3.86(3H,s), 5.00(2H,dd,J=1.2,6.4Hz), 6.40(1H,td,J=6.4,15.9Hz), 6.65(1H,td,J=1.2,15.9Hz), 7.27(2H,d,J=8.8Hz), 7.30(2H,d,J=8.8Hz), 7.79(2H,d,J=9.0Hz), 8.61(1H,brs), 8.62(1H,s).

IR (KBr) cm: 3270,3046,1633,1599,1534,1516,1492,1255, 1173,833,772.

Mass (m/z): 425 (M), 423 (M).

Example 115

Preparation of 4-n-butyrylamino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0268] 4-Amino-2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one and butyric anhydride were processed as in Example 113, whereby the title compound was obtained in a yield of 88.2%.

Colorless needles (chloroform-hexane)

Melting point: 152.1-152.7 DEG C

¹H-NMR (CDCl₃) delta: 1.04(3H,t,J=7.5Hz), 1.70-1.85(2H,m), 2.45(2H,t,J=7.3Hz), 3.86(3H,s), 5.00

(2H,dd,J=1.2,6.4Hz), 6.41(1H,td,J=6.4,15.9Hz), 6.64(1H,td,J=1.2,15.9Hz), 6.96(2H,d,J=8.9Hz), 7.27(2H,d,J=8.8Hz), 7.30(2H,d,J=8.8Hz), 7.79(2H,d,J=8.9Hz), 8.60(1H,brs), 8.62(1H,s).
 IR (KBr) cm: 3271,3051,3034,1632,1598,1532,1517,1500,1258,1172.
 Mass (m/z): 439 (M), 437 (M).

Example 116

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-(N-methylethoxycarbonylamino)-2H-pyridazin-3-one

[0270] In N,N-dimethylformamide, 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one (100 mg) was stirred at 80 DEG C for 1 hour in the presence of methyl iodide and potassium carbonate. The procedures of Example 1 were then repeated likewise, whereby the title compound (92 mg, 89.2%) was obtained.

Slightly yellow fine needles (chloroform-hexane)

Melting point: 130.8-131.5 DEG C

¹H-NMR (CDC l 3) delta : 1.27(3H,t,J=7.1Hz), 3.30(3H,s), 3.86(3H,s), 4.22(2H,q,J=7.1Hz), 5.00(2H,dd,J=1.0,6.3Hz), 6.42(1H,td,J=6.6,15.9Hz), 6.67(1H,td,J=1.0,15.9Hz), 6.97(2H,d,J=9.0Hz), 7.27(2H,d,J=8.7Hz), 7.31(2H,d,J=8.7Hz), 7.63(1H,s), 7.71(2H,d,J=9.0Hz).

IR (KBr) cm: 1706,1655,1611,1520,1316,1307,1252,1176.

Mass (m/z): 455 (M), 453 (M).

Example 117

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-methylamino-2H-pyridazin-3-one

[0272] Using 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-(N-methylethoxycarbonylamino)-2H-pyridazin-3-one (68 mg) as a starting material, the procedures of Example 111 were repeated likewise (stirred at 70 DEG C for 1 hour), whereby the title compound (49 mg, 93.9%) was obtained.

Colorless needles (chloroform-hexane)

Melting point: 148.4-149.2 DEG C

¹H-NMR (CDC l 3) delta : 2.96(3H,d,J=5.1Hz), 3.85(3H,s), 4.96(2H,dd,J=1.2,6.4Hz), 5.77(2H,brq,J=5.1Hz), 6.33(1H,s), 6.42(1H,td,J=6.4,15.9Hz), 6.62(1H,td,J=1.2,15.9Hz), 6.96(2H,d,J=9.0Hz), 7.25(2H,d,J=8.9Hz), 7.30(2H,d,J=8.9Hz), 7.74(2H,d,J=9.0Hz).

IR (KBr) cm: 3318,1630,1606,1519,1432,1240.

Mass (m/z): 383 (M), 381 (M).

Example 118

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-[N-(3-phenylpropyl)ethoxycarbonylamino]-2H-pyridazin-3-one

[0274] Using 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one (70 mg) and 3-phenylpropyl bromide as starting materials, the procedures of Example 116 were repeated likewise, whereby the title compound (61 mg, 68.7%) was obtained.

Colorless fine needles (chloroform-diethyl etherhexane)

Melting point: 113.5-114.2 DEG C

¹H-NMR (CDCI₃) delta : 1.22(3H,t,J=7.1Hz), 1.85-1.98(2H,m), 2.65(2H,t,J=7.7Hz), 3.79(2H,t,J=7.4Hz), 3.86(3H,s), 4.19(2H,q,J=7.1Hz); 4.99(2H,dd,J=1.0,6.3Hz), 6.42(1H,td,J=6.6,15.9Hz), 6.65(1H,td,J=1.0,15.9Hz), 6.97(2H,d,J=8.8Hz), 7.27(2H,d,J=8.9Hz), 7.10-7.33(9H,m), 7.48(1H,s), 7.68(2H,d,J=8.8Hz).

IR (KBr) cm: 1678,1657,1616,1522,1305,1252,1183,1166.

Mass (m/z): 559 (M), 557 (M).

Example 119

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-(3-phenylpropyl)amino-2H-pyridazin-3-one

[0276] Using 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-[N-(3-phenylpropyl)ethoxycarbonylamino]-2H-pyridazin-3-one (31 mg) as a starting material, the procedures of Example 111 were repeated likewise, whereby the title compound (26 mg, 96.3%) was obtained.

Colorless fine needles (chloroform-hexane)

Melting point: 161.2-162.6 DEG C

¹H-NMR (CDCI₃) delta : 1.96-2.09(2H,m), 2.76(2H,t,J=7.4Hz), 3.17-3.26(2H,m), 3.85(3H,s), 4.96(2H,dd,J=1.2,6.4Hz), 5.79(1H,brt,J=5.5Hz), 6.25(1H,s), 6.43(1H,td,J=6.4,15.9Hz), 6.63(1H,td,J=1.2,15.9Hz), 6.95(2H,d,J=8.9Hz), 7.17-7.34(9H,m), 7.68(2H,d,J=8.9Hz).

IR (KBr) cm: 3315,1630,1602,1519,1258,1177,821.

Mass (m/z): 487 (M), 485 (M).

Example 120

Preparation of 2-(4-chlorocinnamyl)-6-(4-methoxyphenyl)-4-[N-(2-pyridylmethyl)ethoxycarbonylamino]-2H-pyridazin-3-one

[0278] 2-(4-Chlorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one (70 mg) and 2-pyridylmethyl bromide were processed as in Example 116 (stirred at 70 DEG C for 4 hours), whereby the title compound (82 mg, 97.0%) was obtained.

Pale brown oil

H-NMR (CDC I 3) delta : 1.18(3H,t,J=7.1Hz), 3.85(3H,s), 4.20(2H,q,J=7.1Hz), 4.98(2H,dd,J=1.0,6.3Hz), 5.05(2H,s), 6.40(1H,td,J=6.6,15.9Hz), 6.63(1H,td,J=1.0,15.9Hz), 6.95(2H,d,J=8.8Hz), 7.11-7.17(1H,m), 7.27(2H,d,J=9.0Hz), 7.29(2H,d,J=9.0Hz), 7.40-7.45(1H,m), 7.59-7.64(1H,m), 7.67(2H,d,J=8.8Hz), 7.78(1H,s), 8.49-8.53(1H,m).
 IR (film) cm: 1716,1660,1652,1610,1519,1305,1252, 1209,1169.
 Mass (m/z): 532 (M), 530 (M).

[0280] In a manner known per se in the art, the monochloride of the title compound was obtained in a yield of 74.2%.

Pale brown amorphous

Melting point: 90 DEG C (softened)

H-NMR (CDC I 3) delta : 1.16(3H,t,J=7.1Hz), 3.85(3H,s), 4.17(2H,q,J=7.1Hz), 5.05(2H,dd,J=1.0,6.4Hz), 5.09(2H,s), 6.48(1H,td,J=6.4,15.9Hz), 6.69(1H,td,J=1.0,15.9Hz), 7.03(2H,d,J=8.8Hz), 7.30(2H,d,J=8.5Hz), 7.40(2H,d,J=8.5Hz), 7.72-7.79(1H,m), 7.83(2H,d,J=8.8Hz), 7.97-8.03(1H,m), 8.16(1H,s), 8.27-8.36(1H,m), 8.69-8.74(1H,m).
 IR (KBr) cm: 1717,1652,1570,1519,1305,1251,1225,1169.

Example 121

Preparation of 4-amino-2-benzyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0282] Using 2-benzyl-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 111 were repeated likewise, whereby the title compound was obtained in a yield of 57.4%.

Slightly brown prisms (chloroform-hexane)

Melting point: 115.1-115.6 DEG C

H-NMR (CDC I 3) delta : 3.85(3H,s), 4.94(2H,br), 5.39(2H,s), 6.95(2H,d,J=8.8Hz), 7.24-7.37(3H,m), 7.47-7.52(2H,m), 7.69(2H,d,J=8.8Hz).
 IR (KBr) cm: 3419,3322,3286,3259,1644,1600,1519,1251, 1184,1021,839.
 Mass (m/z): 307 (M).

Example 122

Preparation of 2-benzyl-4-methanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

(1) Preparation of 2-benzyl-4-dimethanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0284] To a solution of 4-amino-2-benzyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (60 mg, 0.20 mmol) and triethylamine (80 mg, 0.79 mmol) in toluene (1 m l), methanesulfonyl chloride (70 mg, 0.61 mmol) was added, followed by heating under stirring at 40 DEG C for 1 hour. Chloroform was added to the reaction mixture. The organic layer was washed with water and brine, and was then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel preparative chromatography [developer: hexane/ethyl acetate (1/1)], whereby the title compound (76 mg, 90.4%) was obtained.

H-NMR (CDC l 3) delta : 3.55(6H,s), 3.86(3H,s), 5.43(2H,s), 6.70(2H,d,J=9.2Hz), 7.27-7.37(3H,m), 7.42-7.46(2H,m), 7.65-7.70(3H,m).

(2) Preparation of 2-benzyl-4-methanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0285] To a solution of 2-benzyl-4-dimethanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one (36 mg, 0.08 mmol) in methanol (1 m l), a 4N aqueous solution of sodium hydroxide (1 m l) was added, followed by stirring at room temperature for 2 hours. The reaction mixture was acidified with hydrochloric acid under ice cooling, added with water (30 m l), and then extracted with chloroform (20 m l x 2). The organic layer was washed with brine and then dried over anhydrous sodium sulfate. The solvent was distilled off and the residue (31 mg) was crystallized from chloroform-hexane, whereby the title compound (26 mg, 86.9%) was obtained as slightly brown needles.

Melting point: 195.0-195.5 DEG C

H-NMR (CDC l 3) delta : 3.13(3H,s), 3.86(3H,s), 5.40(2H,s), 6.98(2H,d,J=8.8Hz), 7.30-7.39(3H,m), 7.47-7.51(2H,m), 7.75(2H,d,J=8.8Hz), 8.02(1H,br).

IR (KBr) cm: 3151,1634,1599,1440,1250,1154,1021,835, 770,753,700.

Mass (m/z): 385 (M).

Example 123

Preparation of 2-benzyl-4-(3-isopropylureido)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0286] To a solution of 4-amino-2-benzyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one (50 mg, 0.16 mmol) in benzene (2 m l), isopropyl isocyanate (0.1 m l, 1.02 mmol) was added, followed by stirring at 60 DEG C for 17 hours. The solvent was distilled off, and the residue was separated and purified by silica gel preparative chromatography [developer: chloroform/methanol (15/1)]. The crude crystals (63 mg) were recrystallized from chloroform-hexane, whereby the title compound (56 mg, 87.7%) was obtained as colorless needles.

Melting point: 200.2-201.0 DEG C

H-NMR (CDC l 3) delta : 1.15(3H,s), 1.18(3H,s), 3.85(3H,s), 3.92-4.07(1H,m), 5.38-5.52(3H,m), 6.93(2H,d,J=8.9Hz), 7.25-7.45(5H,m), 7.79(2H,d,J=8.9Hz), 8.31(1H,brs), 8.47(1H,s).

IR (KBr) cm: 3370,3283,1698,1624,1592,1517,1255,1175, 1032,830,701.

Mass (m/z): 392 (M).

Example 124

Preparation of 4-amino-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0287] Using 2-cyclopropylmethyl-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 111 were repeated likewise (stirred at 60 DEG C for 40 minutes), whereby the title compound (82 mg, 97.0%) was obtained.

Colorless needles (chloroform-hexane)

Melting point: 110.8-111.3 DEG C

¹H-NMR (CDCl₃) δ : 0.44-0.59(4H,m), 1.35-1.52(1H,m), 3.85(3H,s), 4.09(2H,d,J=7.3Hz), 4.95(2H,br), 6.68(1H,s), 6.95(2H,d,J=8.9Hz), 7.70(2H,d,J=8.9Hz).

IR (KBr) cm: 3455,3300,3261,3206,1641,1601,1575,1520, 1420,1246,1239,1025,835.

Mass (m/z): 271 (M).

Example 125

Preparation of 2-cyclopropylmethyl-4-(3-isopropylureido)-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0289] Using 4-amino-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Example 123 were repeated likewise, whereby the title compound was obtained in a yield of 77.0%.

Colorless needles (chloroform-hexane)

Melting point: 195.8-197.0 DEG C

¹H-NMR (CDCl₃) δ : 0.45-0.62(4H,m), 1.24(3H,s), 1.27(3H,s), 1.34-1.51(1H,m), 3.85(3H,s), 4.00-4.15(3H,m), 5.85(1H,brd,J=7.9Hz), 6.95(2H,d,J=8.9Hz), 7.81(2H,d,J=8.9Hz), 8.53(1H,s), 8.55(1H,brs).

IR (KBr) cm: 3324,1694,1622,1611,1591,1538,1516,1253, 1175,1033,836.

Mass (m/z): 356 (M).

Example 126

Preparation of 2-cyclopropylmethyl-4-methanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

(1) Preparation of 2-cyclopropylmethyl-4-dimethanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0291] Using 4-amino-2-cyclopropylmethyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one as a starting material, the procedures of Examples 122-(1) were repeated likewise, whereby the title compound was obtained in a yield of 90.1%.

¹H-NMR (CDCl₃) δ : 0.43-0.63(4H,m), 1.33-1.49(1H,m), 3.57(6H,s), 3.87(3H,s), 4.13(2H,d,J=7.3Hz), 6.99(2H,d,J=8.6Hz), 7.71(2H,d,J=8.6Hz), 7.72(1H,s).

(2) Preparation of 2-cyclopropylmethyl-4-methanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

[0292] Using 2-cyclopropylmethyl-4-dimethanesulfonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one

as a starting material, the procedures of Examples 122-(2) were repeated likewise, whereby the title compound was obtained in a yield of 81.0%.

Colorless needles (chloroform-hexane)

Melting point: 203.3-203.9 DEG C

¹H-NMR (CDCl₃) delta : 0.45-0.63(4H,m), 1.35-1.50(1H,m), 3.16(3H,s), 3.87(3H,s), 4.12(2H,d,J=7.3Hz), 6.98(2H,d,J=8.8Hz), 7.74(1H,s), 7.75(2H,d,J=8.8Hz), 8.09(1H,br).

IR (KBr) cm: 3124,1641,1604,1583,1517,1448,1347,1253, 1148,1025,864,833.

Mass (m/z): 349 (M)

Example 127

Preparation of 4-carbamoyl-6-(3-chloro-4-fluorophenyl)-2-cinnamyl-2H-pyridazin-3-one

[0294] Using 6-(3-chloro-4-fluorophenyl)-2-cinnamyl-4-ethoxycarbonyl-2H-pyridazin-3-one as a starting material, the procedures of Example 38 were repeated likewise, whereby the title compound was obtained in a yield of 64.8%.

Pale yellow needles (methanol)

Melting point: 211.0-212.0 DEG C

¹H-NMR (DMSO-d₆) delta : 5.05(2H,d,J=5.9Hz), 6.52(1H,td,J=5.9,15.8Hz), 6.68(1H,d,J=15.8Hz), 7.22-7.38(3H,m), 7.47(2H,d,J=6.9Hz), 7.55(1H,t,J=8.9Hz), 7.95-8.02(1H,m), 7.08-8.20(2H,m), 8.59(1H,s), 8.82(1H,brs).

IR (KBr) cm: 3306,3135,1705,1632,1578,1506,1407,1266, 959,816,801,735.

Mass (m/z): 385 (M), 383 (M).

Example 128

Preparation of 4,5-dihydro-2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one

[0296] To a solution of 2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one (50 mg, 0.16 mmol) in N,N-dimethylformamide (10 ml), 10% palladium on charcoal (45 mg) was added, followed by catalytic reduction at 80 DEG C. Fourteen hours later, the catalyst was filtered off, the solvent was distilled off under reduced pressure, and the residue was separated and purified by silica gel preparative chromatography [developer: hexane/ethyl acetate (1/1)]. Crystallization was then conducted from chloroform-hexane, whereby the title compound (22 mg, 43.7%) was obtained as colorless needles.

Melting point: 124.2-125.0 DEG C

¹H-NMR (CDCl₃) delta : 0.926(3H,d,J=6.8Hz), 0.932(3H,d,J=6.8Hz), 2.07-2.24(1H,m), 2.82(3H,d,J=4.6Hz), 3.05-3.17(1H,m), 3.33-3.44(2H,m), 3.65-3.70(2H,m), 3.85(3H,s), 6.93(2H,d,J=9.0Hz), 7.36(1H,br), 8.24(2H,d,J=9.0Hz).

IR (KBr) cm: 3392,3015,1675,1646,1515,1405,1364,1256, 1177,1026.

Mass (m/z): 317 (M).

Example 129

Preparation of 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methylthiocarbamoyl-2H-pyridazin-3-one

[0297] To a solution of 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one (133 mg, 0.40 mmol) in toluene (10 mL), Lawesson's reagent (162 mg, 0.40 mmol) was added, followed by stirring at 85 DEG C for 12 hours under argon. The toluene was distilled off, and the residue was separated and purified by chromatography on a silica gel column [silica gel: 6 g, hexane/ethyl acetate (4/1 to 2/1)]. Crystallization was conducted from chloroform-ethyl acetate, whereby the title compound (109 mg, 78.4%) was obtained as orange needles.

Melting point: 178.0-178.5 DEG C

¹H-NMR (CDCl₃) δ : 0.47-0.63(4H,m), 1.40-1.47(1H,m), 3.39(3H,d,J=4.9Hz), 3.96(3H,s), 4.20(2H,d,J=7.3Hz), 7.03-7.08(1H,m), 7.61-7.64(1H,m), 7.68-7.72(1H,m), 9.26(1H,s), 12.34(1H,br).

IR (KBr) cm: 3111,1641,1548,1521,1506,1425,1289,1267, 1117,1015.

Mass (m/z): 347 (M).

Example 130

Preparation of 2-isobutyl-6-(4-methoxyphenyl)-4-methylthiocarbamoyl-2H-pyridazin-3-one

[0298] Using 2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one as a starting material, the procedures of Example 129 were repeated likewise, whereby the title compound was obtained in a yield of 27.7%.

Orange needles (ethyl acetate-diethyl ether)

Melting point: 116.0-116.6 DEG C

¹H-NMR (CDCl₃) δ : 1.00(6H,d,J=6.6Hz), 2.36(1H,sept.,J=6.8Hz), 3.38(3H,d,J=4.9Hz), 3.87(3H,s), 4.17(2H,d,J=7.3Hz), 7.00(2H,d,J=8.8Hz), 7.85(2H,d,J=9.0Hz), 9.28(1H,s), 12.40(1H,br).

IR (KBr) cm: 2960,1640,1544,1515,1503,1266,1249.

Mass (m/z): 331 (M).

Test 1

(Inhibitory activity against interleukin-1 beta production)

[0300] HL-60 cells were cultured for 4 days until confluence on RPMI 1640 medium with 10% fetal bovine serum (FBS) added thereto. The medium was centrifuged. The supernatant was discarded, and the cells were then suspended at 1 x 10⁶ cells/mL on RPMI 1640 medium with 3% FBS, and lipopolysaccharide was added to give a final concentration of 10 μ g/mL. The culture was inoculated at 1 mL/well to a 24-well plate. A test compound was added at 1 μ L/well, followed by culturing for 3 days. Three days later, the amount of interleukin-1 beta in each IC₅₀ value was determined by a comparison in yield with a control to which no test sample was added. Results on some representative compounds are shown in Table 1.

Id=Table 1 Columns=2

Inhibitory Activity against Interleukin-1 beta (IL-1 beta) Production

Head Col 1: Test compound (Example No.)

Head Col 2: IL-1 beta IC50(mu M)

430.357

610.038

630.31

660.11

870.05

1110.53

1120.387

1280.40

Comp. Comp'd 129

Comp. Comp'd 246

Comp. Comp'd 3>100

Comp. Comp'd 431.6

[0301] As is apparent from Table 1, the compounds according to the present invention have been found to have extremely good IL-1 beta inhibitory activity compared with the comparative compounds, which are the compounds disclosed in EOR. J. MED. CHEM., 14, 53-60, 1979 and are known to have anti-inflammatory and analgesic action.

Capability of Exploitation in Industry

[0302] The pyridazine derivatives (1) and their salts, which pertain to the present invention, have excellent inhibitory activity against interleukin-1 beta production, and are useful as medicines such as preventives and therapeutics for immune system diseases, inflammatory diseases and ischemic diseases.

~~~~~  
Data supplied from the esp@cenet database - I2

### Claims

1. A pyridazine derivative represented by the following formula (1):

wherein R represents a lower alkoxy group, a lower alkylthio group or a halogen atom; R represents a hydrogen atom, a lower alkoxy group, a lower alkylthio group or a halogen atom; R represents a linear or branched lower alkyl or lower alkenyl group, which may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group, a lower cycloalkyl group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted carbamoyl group; R represents a carboxyl group, a lower alkoxy carbonyl group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted thiocarbamoyl group, a substituted or unsubstituted amino group, or a substituted or unsubstituted ureido group; and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond; or a salt thereof.

2. A pyridazine derivative or a salt thereof according to claim 1, wherein the carbon-carbon bond between the 4-position and the 5-position in the formula (1) is a double bond.

3. A pyridazine derivative or a salt thereof according to claim 1 or 2, wherein R represents a fluorine atom, a lower alkoxy group or a lower alkylthio group; and R represents a hydrogen atom, a halogen atom or a lower alkoxy group.

4. A pyridazine derivative or a salt thereof according to any one of claims 1-3, wherein:

R represents a linear or branched alkyl group having 1 to 6 carbon atoms or a linear or branched lower



alkenyl group having 2 to 9 carbon atoms, which may have one or more substituents each independently selected from a hydroxyl group, a halogen atom, a cyano group or a lower cycloalkyl group; a phenyl or pyridyl group which may have 1 to 3 substituents each independently selected from a halogen atom, a nitro group, an amino group or an aromatic-group-substituted carbonylamino group; or a carbamoyl group which may have one or more substituents each independently selected from a lower alkyl group, a hydroxy lower alkyl group, an aromatic-group-substituted lower alkyl group or a lower alkylthiophenyl group; and

R represents a carboxyl group; a lower alkoxy carbonyl group; a carbamoyl or thiocarbamoyl group which may have one or more substituents each independently selected from a lower alkyl group, an aromatic group or an aromatic-group-substituted lower alkyl group; an amino group which may have one or more substituents each independently selected from a lower alkoxy carbonyl group, an aromatic-group-substituted lower alkoxy carbonyl group, an acyl group, a lower alkyl group, an aromatic-group-substituted lower alkyl group or a lower alkylsulfonyl group; or a ureido group which may have one or more lower alkyl groups as substituents.

5. A pyridazine derivative or a salt thereof according to claim 1, which is 2-isobutyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-cyclopropylmethyl-6-(3-fluoro-4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one, 2-cyclopropylmethyl-4-ethylcarbamoyl-6-(4-methoxyphenyl)-2H-pyridazin-3-one, 2-(4-chlorocinnamyl)-4-ethoxycarbonylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one, or 2-(4-chlorocinnamyl)-4-formylamino-6-(4-methoxyphenyl)-2H-pyridazin-3-one.

6. A medicine comprising, as an effective ingredient, a pyridazine derivative or a salt thereof according to any one of claims 1-5.

7. A medicine according to claim 6, which is an inhibitor of interleukin-1 beta production.

8. A medicine according to claim 6, which is a preventive or therapeutic for a disease caused by stimulation of interleukin-1 beta production.

9. A medicine according to claim 6, which is a preventive or therapeutic for an immune system disease, an inflammatory disease, an ischemic disease, osteoporosis or ichorrhemia.

10. A medicine according to claim 6, which is a preventive or therapeutic for rheumatism, arthritis or inflammatory colitis.

11. An inhibitor of interleukin-1 beta production comprising, as an effective ingredient, a pyridazine derivative or a salt thereof according to any one of claims 1-5.

12. A pharmaceutical composition comprising a pyridazine derivative or a salt thereof according to any one of claims 1-5 and a pharmaceutically acceptable carrier.

13. Use of a pyridazine derivative or a salt thereof according to any one of claims 1-5 as a medicine.

14. A method for the treatment of a disease caused by stimulation of interleukin-1 beta production, which comprises administering a pyridazine derivative or a salt thereof according to any one of claims 1-5.

.....  
Data supplied from the esp@cenet database - I2